COVID-19 pandemic

Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

Pfaar, Oliver; Klimek, Ludger; Jutel, Marek; Akdis, Cezmi A.; Bousquet, Jean; Breiteneder, Heimo; Chinthrajah, Sharon; Diamant, Zuzana; Eiwegger, Thomas; Fokkens, Wytske J.; Fritsch, Hans Walter; Nadeau, Kari C.; O’Hehir, Robyn E.; O’Mahony, Liam; Rief, Winfried; Sampath, Vanitha; Schedlowski, Manfred; Torres, Maria José; Traidl-Hoffmann, Claudia; Wang, De Yun; Zhang, Luo; Bonini, Matteo; Breherl, Randolf; Brough, Helen Annaruth; Chivato, Tomás; Del Giacco, Stefano R.; Dramburg, Stephanie; Gawlik, Radoslaw; Gelincik, Asli; Hoffmann-Sommergruber, Karin; Hox, Valerie; Knol, Edward F.; Lauerma, Antti; Matricardi, Paolo M.; Mortz, Charlotte G.; Ollert, Markus; Palomares, Oscar; Riggioni, Carmen; Schwarze, Jürgen; Skypala, Isabel; Untersmayr, Eva; Walusiak-Skorupa, Jolanta; Ansotegui, Ignacio J.; Bachert, Claus; Bedbrook, Anna; Bosnic-Anticevich, Sinthia; Brussino, Luisa; Canonica, Giorgio Walter; Cardona, Victoria; Carreiro-Martins, Pedro; Cruz, Alvaro A.; Czarlewski, Wienczyslawa; Fonseca, João A.; Gotua, Maia; Haahtela, Tari; Ivancevich, Juan Carlos; Kuna, Piotr; Kvedariene, Violeta; Larenas-Linnemann, Désirée Erlinda; Abdul Latiff, Amir Hamzah; Mäkelä, Mika; Morais-Almeida, Mário; Mullol, Joaquim; Naclerio, Robert; Ohta, Ken; Okamoto, Yoshitaka; Onorato, Gabrielle L.; Papadopoulos, Nikolaos G.; Patella, Vincenzo; Regateiro, Frederico S.; Samoliński, Boleslaw; Suppli Ulrik, Charlotte; Toppila-Salmi, Sanna; Valiulis, Arunas; Ventura, Maria Teresa; Yorgancioglu, Arzu; Zuberbier, Torsten; Agache, Ioana

Published in:
Allergy: European Journal of Allergy and Clinical Immunology

DOI:
10.1111/all.14453

Publication date:
2021

Document version:
Accepted manuscript

Citation for published version (APA):
Pfaar, O., Klimek, L., Jutel, M., Akdis, C. A., Bousquet, J., Breiteneder, H., Chinthrajah, S., Diamant, Z., Eiwegger, T., Fokkens, W. J., Fritsch, H. W., Nadeau, K. C., O’Hehir, R. E., O’Mahony, L., Rief, W., Sampath, V., Schedlowski, M., Torres, M. J., Traidl-Hoffmann, C., ... Agache, I. (2021). COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 76(3), 648-676. https://doi.org/10.1111/all.14453
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position Paper

Pfaar O 1*, Klimek L 2*, Jutel M 3 3*, Akdis CA4*, Bousquet J 5 6 7*, Breiteneder H 8, Chinthrajah S 9, Diamant Z 10 11 12, Eiwegger T 13 14 15, Fokkens WJ 16, Fritsch HW 17, Nadeau KC 9, O’Hehir RE 18 19, O’Mahony L 20, Rief W 21, Sampath V 9, Schedlowski M 22, Torres M 23, Traidl-Hoffmann C 24 25, Wang DY 26, Zhang L 27, Bonini M 28 29, Brehler R 30, Brough HA 31 32, Chivato T 33, Del Giacco S 34, Dramburg S 35, Gawlik R 36, Gelincik A 37, Hoffmann-Sommergruber K 8, Hox V 38, Knol E 39, Lauerman A 40, Matricardi PM 35, Mortz CG 41, Ollert M 41 42, Palomares O 43, Riggioni C 44 45, Schwarze J 46, Skypala I 28 47, Untersmayr S 8, Walusiak-Skorupa J 48, Ansotegui I 49, Bachert C 50 51 52, Bedbrook A 7, Bosnic-Anticevich S 53, Brussino L 54, Canonica GW 55, Cardona V 56, Carreiro-Martins P 57, Cruz AA 58, Czarlewski W 7 59, Fonseca JA 60, Gotua M 61, Haatela T 62, Ivancevich JC 63, Kuna P 64, Kvedariene V 65 66, Larenas-Linnemann D 67, Latiff A 68, Morais-Almeida M 69, Mullol J 70, Naclerio R 71, Ohta K 72, Okamoto Y 73, Onorato GL 7, Papadopoulos NG 74 75, Patella V 76, Regateiro FS 77, Samolinski B 78, Suppli Ulrik C 79, Toppila-Salmi S 80, Valiulis A 81, Ventura MT 82, Yorgancioglu A 83, Zuberbier T 84, Agache I 85 86.

*the first 5 authors participated equally in the paper

Short title: The organization of an allergy clinic during a COVID-19 pandemic

1 Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
2 Center for Rhinology and Allergology, Wiesbaden, Germany.

3 Department of Clinical Immunology, Wroclaw Medical University, ALL-MED Medical Research Institute, Wroclaw, Poland.

4 Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.

5 Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany.

6 University Hospital Montpellier, France.

7 MACVIA-France, Montpellier, France.

8 Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

9 Stanford University School of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, United States of America.

10 Dept of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.

11 Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.

12 Dept Clin Pharm & Pharmacol, Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.

13 Translational Medicine Program, Peter Gilgan Centre for Research and Learning, Hospital for Sick Children, Toronto, Ontario, Canada.

14 Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Hospital for Sick Children, Departments of Paediatrics and Immunology, University of Toronto, Toronto, ON, Canada.

15 Department of Immunology, University of Toronto, Toronto, ON, Canada.

16 Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands.

17 Department of Information-Technology (IT), University Hospital Marburg, Marburg, Germany.

18 Allergy, Asthma & Clinical Immunology, Alfred Health, Melbourne, VIC, Australia.
19 Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University and Alfred Health, Melbourne, VIC, Australia.

20 Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland

21 Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Marburg, Germany.

22 Institute of Medical Psychology and Behavioral Immunobiology, University Clinic Essen, Essen, Germany.

23 Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.

24 Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum München, Augsburg, Germany.

25 Outpatient Clinic for environmental medicine, University Hospital, Augsburg, Germany.

26 Department of Otolaryngology, National University of Singapore, Singapore.

27 Department of Otolaryngology Head and Neck Surgery and Department of Allergy, Beijing Tongren Hospital, Beijing, China.

28 Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

29 National Heart and Lung Institute (NHLI), Imperial College London, UK.

30 University Hospital Münster, Department of Allergology, Occupational Dermatology and Environmental Medicine, Münster, Germany.

31 Children’s Allergy Service, Evelina Children’s Hospital, Guy’s and St, Thomas’ Hospital NHS Foundation Trust, London, UK.

32 Paediatric Allergy Group, Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, London, UK.

33 School of Medicine, University CEU San Pablo, Madrid, Spain.

34 Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

35 Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité Universitätsmedizin - Berlin, Germany.

36 Dpt. of Internal Medicine, Allergology, Clinical Immunology Medical University of Silesia, Katowice, Poland.
37 Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

38 Department of Otorhinolaryngology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

39 Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.

40 Department of Dermatology and Allergology, University of Helsinki, and Helsinki University Hospital Inflammation Centre, Helsinki, Finland.

41 Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital, University of Southern Denmark, Odense, Denmark.

42 Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.

43 Department of Biochemistry and Molecular Biology, Chemistry School, Complutense University of Madrid, Spain.

44 Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain.

45 Institut de Recerca Sant Joan de Déu, Barcelona, Spain.

46 Centre for Inflammation Research and Child Life and Heath, the University of Edinburgh, Edinburgh, UK.

47 Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, UK.

48 Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland.

49 Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Erandio, Spain.

50 Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium.

51 Sun Yat-sen University, International Airway Research Center, First Affiliated Hospital Guangzou, China.

52 Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden.

53 Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia.

This article is protected by copyright. All rights reserved.
54 Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino & Mauriziano Hospital, Torino, Italy.

55 Personalized Medicine Asthma & Allergy Clinic-Humanitas University & Research Hospital, IRCCS-Milano, Italy.

56 Allergy Section, Department of Internal Medicine, Hospital Vall d’Hebron & ARADyAL research network, Barcelona, Spain.

57 Serviço de Imunoalergologia, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Portugal; NOVA Medical School/Comprehensive Health Research Center (CHRC), Universidade Nova de Lisboa, Lisbon, Portugal.

58 ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and GARD/WHO Executive Committee, Bahia, Brazil.

59 Medical Consulting Czarlewska, Levallois-Perret, France.

60 CINTESIS, Center for Research in Health Technologies and Information Systems, Faculdade de Medicina da Universidade de Porto, Porto, Portugal and MEDIDA, Lda, Porto, Portugal.

61 Center of Allergy and Immunology, Tbilisi, Georgia and David Tvildiani Medical University in Tbilisi, Tbilisi, Georgia.

62 Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.

63 Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.
64 Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland.

65 Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

66 Institute of Clinical medicine, Clinic of Chest diseases and Allergology, faculty of Medicine, Vilnius University, Vilnius, Lithuania.

67 Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.

68 Allergy & Immunology Centre, Pantai Hospital Kuala Lumpur, Malaisia.

69 Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.

70 Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic - Clinical & Experimental Respiratory Immunology, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.

71 Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

72 National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.

73 Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.

74 Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children’s Hospital, University of Manchester, Manchester, UK.

75 Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital "P&A Kyriakou," University of Athens, Athens, Greece.
Allergy and Respiratory Diseases, Department of Internal Medicine, IRCCS San Martino-IST-University of Genoa, Italy.

Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra and Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland.

Dept of Respiratory Medicine, Hvidovre Hospital, Hvidovre and Institute of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Denmark.

Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Vilnius University Faculty of Medicine, Institute of Clinical Medicine & Institute of Health Sciences, Vilnius, Lithuania.

Interdisciplinary Department of Medicine, University of Bari Medical School, Unit of Geriatric Immuinoallergology, Bari, Italy.

Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey.

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, a member of GA²LEN, Berlin, Germany.

Transylvania University, Brasov, Romania.

Theramed Medical Center, Brasov, Romania.

Corresponding author:
Prof. Dr. med. Oliver Pfaar
Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany
Baldingerstr
D-35043 Marburg
Germany
E-mail: oliver@pfaar.org
Telephone: +49 6421 58 66479

Abbreviations

AAAAI, American Academy of Allergy, Asthma and Immunology
ACT, Asthma Control Test
AD, Atopic Dermatitis
AIT, allergen immunotherapy
AR, Allergic Rhinitis
ARIA, Allergic Rhinitis and its Impact on Asthma
BAD, British Association of Dermatologists
BAL, bronchoalveolar lavages
BSL, Biosafety Level
CRF, case report form
CRS, Chronic Rhinosinusitis
CRSwNP, chronic rhinosinusitis with nasal polyps
CRU, Clinical Research Unit
COVID-19, corona virus disease 2019
DMZ, demilitarized zones
EAACI, European Academy of Allergy and Clinical Immunology
ECDC, European Centre for Disease Control
EPIT, epicutaneous immunotherapy
ERS, European Respiratory Society
ETFAD, Task Force on Atopic Dermatitis
EHR, Electronic Health record
EMA, European Medicines Agency
ENT, Ear, Nose and Throat
Abstract

Background: The Coronavirus disease 2019 (COVID-19) has evolved as a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-)2. Allergists and other health care providers (HCPs) in the field of allergies and associated airway diseases are in the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics.

Method: The scientific information on COVID-19 was analyzed by a literature search in Medline, Pubmed, national and international guidelines from the
European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library and the Internet.

**Results:** Based on diagnostic and treatment standards developed by EAACI, on international information regarding COVID-19, on guidelines of the World Health Organization (WHO) and other international organizations as well as on previous experience, a panel of experts including clinicians, psychologists, IT experts and basic scientists along with EAACI and the “Allergic Rhinitis and its Impact on Asthma (ARIA)” initiative have developed recommendations for the optimal management of allergy clinics during the current COVID-19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies.

**Conclusions:** This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients whilst ensuring necessary safety in the current COVID-19 pandemic.

**Keywords:** COVID-19, allergen immunotherapy (AIT), SARS-CoV-2, allergy clinic, asthma, anaphylaxis, clinical trials, psychological COVID, position paper

**Introduction**

On March 11, 2020, the World Health Organization (WHO) declared the “corona virus disease 2019 (COVID-19)” as a pandemic viral disease. Since the first transmission dynamics reported in China [1], the number of infected patients and fatalities have been increasing worldwide [2]. Typical symptoms of COVID-19 include general malaise, fever, respiratory problems, and especially cough and shortness of breath. The clinical pattern differentiates somewhat from other airway diseases (Table 1).

**INSERT: TABLE 1**
Table 1: Differences and similarities in the clinical pattern of COVID-19, common cold, flu, allergic rhinitis, chronic rhinosinusitis and allergic asthma (modified from [3]).

Other symptoms include muscle and joint pain, sore throat, headache, nausea or vomiting, diarrhoea, nasal symptoms, and especially dysfunction in smell and loss of taste. In about 80% of the registered cases, the disease shows a milder and transient course. However, in about 5% of patients, admission to the intensive care unit (ICU) is necessary due to hypoxaemia and extensive pneumonia, often resulting in respiratory failure due to severe acute respiratory syndrome, often accompanied by coagulopathy and pulmonary embolism and the involvement of other organs including kidney, heart, and the central nervous system [4] [5] [2]. Preventive measures have been implemented worldwide to adjust ambulatory health services and decrease direct patient contacts to a minimum. However, until now, there is no clear advice on how to manage allergic patients with co-morbid COVID-19 or non-SARS-CoV-2 infected allergic patients during the ongoing pandemic [6]. The European Academy of Allergy and Clinical Immunology (EAACI) in alliance with the global initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA) has published several recommendations and assessments in the field of allergic diseases such as allergic rhinoconjunctivitis (ARC), allergic asthma and others [7] regarding pharmacotherapy, Allergen Immunotherapy (AIT), biological treatment and others [5] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18].

As allergists and other healthcare providers (HCPs) with a focus on allergic diseases are frequently treating patients with manifestations of atopic disease in the upper and lower airways, they are on the front line in caring for patients potentially infected with SARS-CoV-2. As such, the clinical setting in an allergy outpatient clinic or hospital must ensure optimal care for the patients as well as sufficient prophylactic measures to minimize risks of infection for both the medical personnel and the patients requiring treatment as reported in an academic Allergy Centre initiative [19]. Therefore, clinical procedures in allergy clinics and outpatient practices must be optimized and standardized, within the contextual considerations regarding national regulations [20].

The aim of this Position Paper - prepared by EAACI in collaboration with ARIA - is to provide allergy clinics, specialized centres and practices with practical recommendations on measures for daily practice and optimal care for allergic
patients during the current COVID-19 pandemic. These recommendations are grouped into nine sections (key-conclusions in table 2) as elaborated by experts including clinicians, psychologists, information technology (IT) experts and basic scientists in the field of allergy. These recommendations are conditional and should be adapted regularly on the basis of evolving clinical evidence.

| Section | Key-conclusions |
|---------|-----------------|
| I. COVID-19: General considerations for HCPs | Protective measures should be taken following the general recommendations from the European Centre for Disease Control and the World Health Organization and current rules must comply with the national responsible government agencies. |
| II. COVID-19: clinical course in allergic patients | Viral infections, including infections with Coronaviruses, are associated with aggravation of allergies such as asthma exacerbations. Limited knowledge is available on the differences in the course of COVID-19 infection in allergic compared to non-allergic patients and further clinical evidence is needed. |
| III. Care of allergic patients: preclinical setting and triage of patients | Many clinics and medical offices already use remote health care tools to triage and manage patients after hours and as part of usual practices. These measures can ideally be used to prioritize and triage allergic patients on the basis of the severity of the allergic disease, the need for in-person consultation and the differentiation of allergic symptoms from clinical symptoms of COVID-19. |
| IV. Challenges and Chances of Information Technology (IT) | Digital health solutions, especially the use of telemedicine, has been previously proposed as a useful tool to provide medical advice remotely when physical presence is impossible or should be limited to a strict minimum such as in the current COVID-19 pandemic. However, certain limitations of this technology need to be considered and special emphasis should be placed on data-security and -protection. |
V. Clinical Setting

General hygiene rules should be followed, especially in the preclinical and clinical setting. The entrance, which is the first point of contact, further patient traffic organization as well as the triage of allergic patients should be organized to minimize the risks of viral infection. Moreover, the organization of staff should be optimized and regular training of procedures should be provided. Any physical contact with the patient should be minimized, and effective preventive measures should be carried out for any further examination and diagnostic.

VI. Specific considerations in diagnostic procedures in allergic patients

Specific considerations in a clinical setting are necessary for the diagnostic procedures of different allergic diseases during the current pandemic. As SARS-CoV-2 spreads primarily through respiratory aerosols, airways but also other allergy-related organs are affected and preventive measures should be ensured. These comprise ENT exams (including endoscopy), bronchoscopy, nasal or bronchial allergen provocation tests, tissue-sampling, lung function tests, skin testing and blood-sample collection, drug provocation tests, oral food challenges and esophageal exams.

VII. Specific considerations in the management of different allergic diseases

Though avoidance measures during the COVID-19 pandemic are similar in different allergic diseases, specific aspects should also be followed in optimal care for allergic rhinoconjunctivitis, asthma, atopic dermatitis, chronic rhinosinusitis, drug allergy, food allergy, urticaria and venom allergy. Different recommendations can be provided for patients with suspected SARS-CoV-2 infection or diagnosed COVID-19 disease versus noninfected individuals or patients having recovered from COVID-19 infection.
| Section | Description |
|---------|-------------|
| VIII. Socio-psychological considerations for allergic patients and optimal care during and after the pandemic | Socio-psychological mechanisms play a major role in terms of symptom development, symptom exacerbation and perception in allergic patients. Besides, the general population is highly sensitive to the perception of people showing respiratory symptoms during the COVID-19 pandemic. This increases the risk of stigmatization of patients with allergies, further increasing the psychosocial stress of patients. Therefore, optimal medical and psychological care for patients with allergies during the COVID-19 pandemic is essential. |
| IX. Considerations for performing non-COVID-19-related clinical trials | Clinical trials to combat the COVID-19 pandemic currently have top priority. However, a number of non-COVID-19 trials are also essential and should be continued if they can be conducted in a safe manner. Safety measures and new guidelines need to be established for participants, and research/laboratory staff dealing with non-COVID-19 related clinical trials to ensure the continuation of essential and critical non-COVID-19 trials. |

Table 2: Key conclusions on the practical considerations on the organization of an allergy clinic during the current COVID-19 pandemic.

I. COVID-19: General considerations for HCPs
Viral respiratory infections like COVID-19 are most often transmitted by direct contact with the virus from the nose, mouth, or coughed / sneezed in droplets from an infected individual [2, 21]. Hand-to-hand contact, inhaling particles from the air after an infected person has coughed or sneezed or touching an infected surface are also common transmission mechanisms. Recommendations for allergic patients - just as for all subjects - include thorough hand washing with soap and
water, frequent use of hand sanitizers, avoidance of people with cold-like symptoms, and taking prescribed medications to optimally control upper and/or lower airway disease.

Patients with a suspected or confirmed diagnosis of COVID-19 should wear a face mask [22] and be treated and examined in an individual room with the door closed. Ideally an isolation room should be used and equipped with technical measures to protect against airborne infectious agents [2, 21].

HCPs are at risk of contracting COVID-19, primarily through droplet spread, with the droplets containing a high reservoir of viral load [23]. If any procedures involving the airway are strictly necessary for COVID-19 positive patients, it must be ensured that staff are supplied with the necessary personal protective equipment in order to avoid infection and possible fatalities. Filtering face-piece (FFP2/FFP3) masks, full eye protection or PAPRs (Powered, Air Purifying Respirators) and further measures are recommended [24].

In accordance with WHO [25] and the European Centre for Disease Control (ECDC [26]), preventive measures are recommended:

- keep a distance of at least 1.5-2 meters from other people (social distancing)
- promote compliance with general hygiene measures such as regular hand disinfection (using an effective disinfectant) / hand washing for at least 30 seconds, avoid touching face and mucous membranes with your hands
- minimize social contacts (social distancing)
- limit direct patient contacts to a strict minimum
- wear personal protective clothing
- encourage regular surface disinfection, especially door handles etc.

Conclusions: Protective measures should be taken following the general recommendations from the European Centre for Disease Control and the World Health Organization and current rules must comply with the national responsible government agencies.
II. COVID-19: clinical course in allergic patients

Coronaviruses, just like the common cold viruses, may be associated with aggravation of asthma exacerbations [27] by stimulation of type 2 immune response associated cytokine production in infected epithelial cells [28]. Allergic diseases might predispose to viral infections or a deferred viral clearance due to delayed and deficient production of the innate type I and type III interferons and/or deficient epithelial barrier function [29] [30].

Until now, limited knowledge has been available on the differences in the course of COVID-19 infections in allergic compared to non-allergic patients. Three studies from Wuhan reported allergic diseases (asthma, allergic rhinitis, atopic dermatitis, urticaria or drug hypersensitivity) as co-morbidities of COVID-19 patients [8] [31] [5]. In a study from Lombardy including over 1,500 patients, 13% of COVID-19 patients admitted to intensive care had asthma [4]. In none of these studies a prolonged or aggravated disease course was reported for patients with allergic disease compared to the included non-allergic cases. In COVID-19 patients from the Seattle area, 3 out of 24 patients developed severe respiratory failure after systemic glucocorticoid treatment due to asthma exacerbation [32]. In the US, higher asthma rates were found in COVID-19 hospitalized adult patients, especially those between 18 and 49 years. However, no information was available as to whether the asthma was caused by allergies [33]. A recent preliminary report suggested modulation of ACE-2 receptor levels by type 2 inflammation, which might shed new light on the role of type 2 immunity in SARS-CoV2 infections and the COVID-19 disease course [34]. Without any doubt, more scientific evidence is needed to answer the question as to whether allergic diseases or the treatment of allergic diseases might predispose patients for COVID-19 development and disease course.

Conclusions: Viral infections, including infections with Coronavirus, are associated with aggravation of allergies such as asthma exacerbations. Limited knowledge is available on the differences in the course of COVID-19 infection in allergic compared to non-allergic patients and further clinical evidence is needed.
III. Care of allergic patients: preclinical setting and triage of patients

Provision of the appropriate level of necessary medical care for patients with allergic diseases and asthma needs to be based on the following principles:

1. Delay elective ambulatory provider visits
   a. Assess the patient’s ability and resources to engage in home monitoring
   b. Select the patients needing direct consultation based on proper screening protocols
   c. Re-schedule any non-essential procedure that might impact on the safety of the patient and the HCP (e.g. lung function testing, airway samplings, rhinoscopy, surgery, drug/food/venom provocation tests)

2. Implement remote health care tools

Many clinics and medical offices already use these remote health care tools to triage and manage patients after hours and as part of usual practices. However, there are several core procedures that need to be taken into account. Primarily, sufficient numbers of health care providers (HCP) should be identified to conduct telephone and telehealth interactions with patients to identify COVID-19 symptoms. They should be assigned and followed by proper advice on the basis of the differentiation of COVID-19 symptoms from symptoms due to the common cold, flu, allergic rhinitis, chronic rhinosinusitis and allergic asthma (Table 1). For this purpose, telemedicine is a useful instrument, but should be provided by a dedicated HCP [35] [36] strictly following the general prerequisites of Information Technology (section IV). The triage of urgent cases is highly important to determine those needing in-person consultation and diagnostic procedures and those who can be managed effectively via telemedicine or scheduled for later dates. However, this important triage should not be undertaken by a medically untrained call centre operator. Individual demands for allergy testing need to be evaluated by experienced nurses or doctors with dedicated skills in taking an allergological history [36]. The technique of documenting allergological history in telemedicine follows generally accepted principles of medical conversation. Standardized and validated questionnaires for quantifying symptoms can complement the analysis of the history, be prefilled by the patient before telemedicine consultation, document the collected data and facilitate computer-assisted evaluation [37]. Patients with a clear need for in-person consultation in
the allergy clinic (Figure 1) should be identified, triaged to the clinic and instructed on the procedures to be followed in the clinic.

INSERT: Figure 1 here

Figure 1: Proposed criteria for in-person consultation of allergic patients. These recommendations should be considered as general guidelines that always need to be adapted to suit the needs of individual patients, the capabilities of the facility itself, and must comply with the relevant and current rules from the responsibility government agency. (ACT, Asthma Control Test; AD, Atopic Dermatitis; ARIA, Allergic Rhinitis and its Impact on Asthma; AR, Allergic Rhinitis; CRS, Chronic Rhinosinusitis; EOE, Eosinophilic Esophagitis; EPIT, epicutaneous immunotherapy; PEF, Peak Expiratory Flow; OIT, oral immunotherapy; SCIT, subcutaneous AIT).

For milder forms, patients should be offered alternative solutions whenever possible to avoid any unnecessary risks associated with a real-life consultation, e.g., shipping electronic inhalation monitoring devices, peak-flow meters, and providing prescription for medication (see section “clinical setting”). In particular, allergic patients with mild symptoms regularly attending the outpatient clinic should be instructed to continue their medication including inhaled corticosteroids (ICS) and intranasal corticosteroids (INCS), AIT and biologicals targeting the T2 immune response as prescribed. Whenever possible, on-site administration in clinics for sublingual AIT and biologicals should be replaced by (self) administration at home with close monitoring, and sufficient supplies of medication should be provided. Local community organisations and health services could be engaged to assist patients who are treated at home and who may need support services in order to ensure optimal care. In some cases, trained clinic nurses can assist by telephone. Additionally, these patients should be well instructed regarding proper prevention measures for allergen exposure control, e.g. using peak-flow measurements or Apps [38] [39] [40], and food avoidance [41] (especially with online ordering and shipping where no individual selection of food is feasible). They
should also be motivated to notify their HCPs in the case of exacerbation or deterioration of symptoms which cannot be appropriately managed at home.

**Conclusions:** Many clinics and medical offices already use these remote health care tools to triage and manage patients after hours and as part of usual practices. These measures can ideally be used to prioritize and triage allergic patients on the basis of the severity of the allergic disease, the need for in-person consultation and the differentiation of allergic symptoms from clinical symptoms of COVID-19.

IV. Challenges and Chances of Information Technology (IT)
Combining the need for regular consultations and the highest degree of protection for both patients with allergic conditions and healthcare workers is a significant challenge in the current pandemic. Digital health solutions, especially the use of telemedicine, have been previously proposed as a useful tool to provide medical advice remotely when physical presence is impossible [42] [36] [43] [44]. These technologies are now significantly gaining momentum [45]. However, certain limitations need to be considered.

As such, Electronic Health Records (EHRs) have now been adopted by most major healthcare organizations. They facilitate remote access and offer greater flexibility than paper-based medical records, a factor that is particularly important during the major clinic restructuring that is occurring during the current COVID-19 pandemic. Here we discuss some of the online tools and apps that can aid researchers, clinicians and other healthcare staff in working with each other (team communications) and with patients (clinical encounters) while working at different locations.

**Cybersecurity**
Every internet connection to other communication partners also involves a certain risk. Normally, clinical and company IT networks are secured from external networks - e.g. the internet - by a complex security infrastructure such as firewalls, separate security zones (DMZ = demilitarized zones), web content filters, intrusion detection systems and virus scanners. These systems protect internal...
clinical networks and also protect from hacker attacks and insecure processes from the internet.

If a videoconferencing system has security gaps, the ‘own network’ can become compromised, up to the installation of malware. A few weeks ago, the US Federal Bureau of Investigation (FBI) issued a warning on the security gaps in video conferencing systems [46]. Security gaps were discovered in the popular communication platform ZOOM ("Zoom vulnerability would have allowed hackers to eavesdrop on calls"[47]). The use of dedicated computers only for this purpose which are operated in a separately secured DMZ is recommended for video conferencing.

Data protection and legal regulations

The use of messenger and / or video services in the healthcare sector is particularly worrying from a data protection perspective. It is a classic area handling particularly "sensitive" and protected data. The processing of healthcare data is even prohibited for the time being according to Art. 9 Para. (1) of the General Data Protection Regulation (GDPR) [48]. Exceptions to this may be for data processing, insofar as processing is necessary for medical diagnostics, care or treatment in the health or social field; exceptions may be possible according to Art. 9 Para. (2) of the GDPR [48].

In this context it should be noted that:

- When using videoconferencing apps, the terms and conditions and privacy policies of the providers must be observed.
- Usage should be conducted in compliance with institution-specific policies and country-specific laws
- Most of these apps prohibit commercial use of the service without a separate agreement. This may call into question the lawful use of these apps for healthcare communications.
- If the user agrees to the Legal Infos of the apps, he/she often grants the manufacturers of the apps the rights of use of the transferred data, images etc.. When transmitting personal data, this means a violation of the basic
data protection regulation and, if applicable, of medical confidentiality, since unauthorized third parties have access to this data [49].

Team communication
Commonly-used team communication applications include Microsoft Teams “Teams”[50], Zoom[51], Box[52], WhatsApp[53], and Slack[54] (Table 3). However, these services should not be used to talk about sensitive health data of identifiable persons, but only for team organizational matters.

| Communication Activity                  | Technology                                      |
|-----------------------------------------|------------------------------------------------|
| Team communications                     | Microsoft Teams, Zoom, Box, WhatsApp, Slack     |
| Educational forums                      | Zoom, Microsoft Teams                           |
| Patient encounters/communication        | Telephone, messenger services *, secure email, Telemedicine (Amwell, Doctor on Demand, Healthtap, MDLive, Teladoc, ZocDoc, Video visits via EHR and others) |
| Research/ Quality Initiatives            | REDCap, Box, R markdown                         |

Table 3: Commonly-used team communication applications. *The use of these services for patient communication is only lawful in the case of very well informed written consent of the patient who must be aware of any risks.

Easy accessibility, reliability, video conferencing, private messaging, creation of distinct channels for relevant discussion, and privacy are all important considerations. There exist popular tools that enable online video conferencing, screen sharing, chats, and file sharing. Only the apps approved by the hospital’s legal department should be used. They can be used for small teams or for larger and more formal meetings, such as weekly unit meetings covering inpatient activity and consultations with relevant educational background. Post-clinic Multi-Disciplinary Meetings (MDM) remain achievable and desirable to ensure that best practice standards are met and can be hosted on “Teams”. Another popular tool is
“Box,” where private health information can be stored and the password encrypted. Folders and documents can be shared and different levels of access can be provided. Document versions can be managed and archived in an easily accessible and convenient manner. There are also a number of cell phone apps that can be used to communicate with smaller groups. In addition to individually owned cell phones, additional cell phones can be shared by members of nursing and administration staff. Office phones can be forwarded to these ‘hot’ phones. Call forwarding between cell phones should be utilized based on a roster for receiving incoming calls.

Many of these tools allow the generation of distinct channels to capture relevant discussions and to ensure patient follow-up. These can include clinic-specific channels to capture logistics of billing, scheduling, rebooking and deferring patients, as well as patient-specific channels to capture follow-up required by nurses and doctors. For all channels, the ability to ‘tag’ staff and reply to comments can be utilized.

Clinical Encounters
Virtual doctor consultations as an alternative to on-site clinical encounters are increasing amid the coronavirus pandemic. Patient communications can take place via telephone, telemedicine/video, secure email, and texting apps (Figure 2):

INSERT: Figure 2 here

Figure 2: Remote communication between the HCP and the patient. EHR, Electronic Health record

Video visits with a virtual care environment within the EHR platform are also being offered [55]. It is recommended that an approved, certified procedure should be used for the patient-related video consultation. These are subject to the respective legal regulations in the individual countries. It is important that the patient should be informed and should give his/her consent for the video consultation. This must be documented in order to have legal security in the case of complaint by the patient. Furthermore, it is important to have a direct “peer to peer” connection between the doctor’s video workplace and the patient’s workplace in order to prevent unauthorised third parties from recording the video stream.
Corresponding security aspects must be taken into account (see also “cybersecurity“).

Conclusions: Digital health solutions, especially the use of telemedicine, has been previously proposed as a useful tool to provide medical advice remotely when physical presence is impossible or should be limited to a strict minimum such as in the current COVID-19 pandemic. However, certain limitations of this technology need to be considered and special emphasis should be placed on data-security and protection.

V. Clinical Setting

Public transport to and from a COVID-19 hospital

Transportation to and from the hospital should follow common healthcare recommendations. Public transport should have clear signs that it is going to the COVID-19 specialty hospital. At the last stop, the bus should be thoroughly disinfected. The driver’s seat should be protected by a transparent plastic wall and the patients should be at least 2 metres away [56]. The front door of the bus should not open for passengers; only the middle and back doors should be used.

General hygiene rules

SARS-CoV-2 is an enveloped virus, which means it is susceptible to common hard-surface disinfectants such as soap and alcohol. Hand sanitizers should be provided in every patient room (ideally both inside and outside of the room), in other patient care and common areas, and at all entrances to the building. Sinks should be well stocked with soap and paper towels. High-touch surfaces, such as door handles, need to be regularly cleaned with hospital grade approved disinfectant solutions or diluted bleach.

Entrance to the Clinic

A hospital should have only two entrances for the patients: one for emergencies and one for non-emergencies. The emergency entrance should have full patient isolation equipment. The triage doctor should immediately determine the need for
full isolation of the patient. Patients who present with an acute respiratory illness and require hospital admission should be tested for SARS-CoV-2 RNA expression by RT-PCR on admission and placed in isolation until the results are ready [57]. Healthcare, cleaning and kitchen staff should all use a separate entrance. The entrance should be near the dressing rooms with two doors. At the non-emergency entrance to the hospital, masks and gloves should be provided for anyone who enters and it should be obligatory to wear these items. Visitors should be actively discouraged from entering the hospital if possible and in line with local recommendations and outpatients should be pre-assessed and triaged accordingly (see section III). Patients should wear a surgical mask and gloves, and perform strict and repeated hand hygiene. A separate toilet/bathroom/commode should be used for virus RNA RT-PCR positive patients.

**Staff organization**

In order to reduce the risk of the healthcare workers becoming infected, which would result in service disruption, new forms of staff deployment need to be elaborated. The personnel in the triage area should wear a FFP2/3 mask as well as a face shield, goggles, gown, gloves, and closed shoes.

A two-team approach has been adopted in many large hospital-based departments with no or minimal contact between the two teams. A popular method involves:

1. **“Team One”**: Inpatient COVID-19 deployment including Consultant, Senior Registrar, Junior Medical Officer. Several such groups could form a roster depending on unit and hospital size.
2. **“Team Two”**: Outpatient allergy/asthma/immunology predominantly operating a virtual call centre approach and ideally remotely operating in staff homes.

A designated deputy head of department and subleads for Allergy/Asthma/Immunology provide a backup framework for key personnel in the case of staff infection requiring substantial self-isolation and resulting in workforce disruption. In COVID-19 patient-overloaded clinics, day and night shifts can be decreased to 6 hours in order to avoid extreme fatigue and thus reduce the risk of HCP errors and infection. Moreover, there is an urgent need for staff training resources and mechanisms to ensure a constant re-training of the most important policies. This regular training has to involve all of the staff members.
Patient organization

Any service that does not require a diagnostic or onsite therapeutic procedure should be undertaken via telemedicine consultation [58].

For regular non-acute care: only patients requiring a timely diagnostic or therapeutic procedure should be seen in the hospital. A history of identifying potential infected contacts, recent travel and early symptoms such as anosmia and dysgeusia [59] [60] should be obtained from all patients before any in-person consultation in the clinical setting [61]. There is now ample evidence that COVID-19 may be contagious before the onset of the classical symptoms of cough and high fever [8]. Therefore, identifying the early symptoms of COVID-19 is of particular importance and is a health system priority. Recently, a probable association between COVID-19 and altered olfactory and gustatory function has been reported by several groups, often as the presenting symptom [60] [62]. To evaluate whether this could be a first symptom of COVID-19 can be particularly challenging when treating allergic and rhinosinusitis patients.

Establishing COVID-19 free zones in the hospital includes a strict screening protocol to ensure that patients who are entering the clinic are not infected by COVID-19. Patients who have indications of potential COVID-19 infection (classical COVID-19 symptoms, fever, but also anosmia, and/or recent contact with a COVID-19 positive subject) should not be admitted to these areas [63]. These patients should be guided to the COVID-19 clinic for further screening evaluation.

To decrease the density of patients, the waiting area should be separate from the treatment area, the number of appointments reduced, and appointments should be scheduled with ample time intervals and online consulting services whenever possible [64]. Precise appointment times are particularly important during the COVID-19 pandemic as this can greatly reduce patient-patient and patient-HCP hospital-acquired cross-infections. Also, precise appointments can ensure that patients stay in the hospital for a minimum amount of time and that the medical staff are fully prepared with personal protective equipment. Moreover, the patient should be admitted to a consulting room with good ventilation and, at the same time, there
should not be more than one patient in the waiting area for visiting or post-immunotherapy observation.

**In the consultation room**

All physical contact with the patient should be limited to a strict minimum. When caring for a patient with suspected COVID-19, staff are recommended to wear a gown, gloves, and either an FFP/FFP2 (or local equivalent) respirator plus face shield and goggles, or a powered air-purifying respirator. However, in hospital areas outside potential SARS-CoV-2 contaminated zones, there is conflicting advice on the necessary level of personal protective equipment (even when available), and evidenced-based recommendations are scarce. Gloves and face masks [22] may be considered for use near entrances and in common areas. Personal protective equipment should be available at the entrance of patient rooms and in other areas where patient care is provided. Signs at the entrance of patient rooms should clearly indicate the level of personal protective equipment required.

Diagnostic procedures involving upper airway manipulation like anterior rhinoscopy and, even more, nasal endoscopy, or nasal provocation should be considered as high risk for viral transmission. These procedures should therefore be limited to patients with an urgent need of examination during the initial phase of the COVID-19 outbreak. For further details, see nasal endoscopy during COVID-19 [24].

**Conclusions:** General hygiene rules should be followed, especially in the preclinical and clinical setting. The entrance, which is the first point of contact, further patient traffic organization as well as the triage of allergic patients should be organized to minimize the risks of viral infection. Moreover, the organization of staff should be optimized and regular training of procedures should be provided. Any physical contact with the patient should be minimized, and effective preventive measures should be carried out for any further examination and diagnostic.

VI. Specific considerations for diagnostic procedures in allergic patients
The following sections overview the specific considerations for diagnostic procedures in different allergic diseases in a clinical setting during the current pandemic. The indication and the urgency for these tests should be taken into account and can be confirmed, for example by an initial visit performed via telemedicine. Contraindications for skin tests, provocation tests and lung function tests can be clarified, and this can help to avoid unnecessary in-person consultation with patients during the COVID-19 pandemic.

**ENT examination, nasal provocation testing and sampling procedures**

SARS-CoV-2 spreads primarily through respiratory aerosols, and higher viral loads have been detected in nasal swabs compared to other locations [65]. Thus, rhinoscopy, nasal endoscopy, nasal provocation testing, smell- and taste testing and samplings are high-risk procedures. Nasal provocation tests should be avoided, whereas rhinoscopy, endoscopy and nasal samplings should be limited to patients with an urgent need for examination [64]. A tower with camera, screen and light source can maximize the examiner-patient distance during endoscopy [24]. The use of anaesthetic spray can be replaced by a soaked pledget, thus avoiding virus atomization [24]. The examiner should wear the adequate personal protective equipment recommended for HCPs: FFP2 or FFP3 face mask, goggles or disposable face shield covering the front and sides of the face, clean gloves, and clean isolation gown [66].

**Lung Function Testing, bronchoprovocation tests and lower airway sampling**

Aerosols can be generated during spirometry, bronchoprovocation testing, fractionated exhaled nitric oxide (FeNO) measurement and other lower airway sampling procedures [67] [68] [69]. Therefore, routine lung function testing and related procedures should be generally suspended during the current pandemic. In cases of extreme need, the personnel should use personal protective equipment and follow the other safety measures as described above [66] [70].

**Skin testing and blood-sample collection for diagnostic use**

This article is protected by copyright. All rights reserved
Skin testing should be generally suspended during the current pandemic. Nevertheless, exceptions can be considered after a careful/proper risk-benefit assessment or may be replaced by laboratory tests. When collecting biological samples or conducting skin testing, the personnel must use the recommended personal protective equipment [66] and also follow the standard precautions (SP) when handling clinical specimens, all of which may contain potentially infectious materials [71]. In this case, a laboratory gown and a single-use waterproof apron may replace the isolation gown [72] [73]. After collection, samples should be placed in a leakproof primary container, and inserted into watertight secondary packaging with absorbent material. This package should be placed in a rigid outer packaging with appropriate labelling [74]. Sample processing should be performed following biosafety level 2 (BLS-2) practices, the current standard in clinical laboratories. Aerosols can originate from centrifugation, pipetting, vortexing, mixing, decanting liquids, loading and spilling samples or cleaning up spills. Therefore, these procedures should be performed inside a biological safety cabinet and using centrifuge safety cups and sealed rotors [71]. Work surfaces and equipment should be appropriately decontaminated and laboratory waste should be handled as biohazardous agents [75]. The inactivation of serum samples suspected to be contaminated with SARS-CoV-2 should be carried out by following the procedure recommended by WHO for serum samples for ELISA-based analysis [76].

Sample collection for research use
Research procedures involving virus isolation and propagation in cell culture should be conducted in a BSL-3 laboratory [77]. The appropriate minimum containment measures for research procedures other than virus propagation (e.g. flow cytometry) are currently unclear. The addition of a virus-neutralizing agent to research samples might be considered to ensure safe processing under BSL-2 conditions [77].

Drug Provocation Tests
Cough, sneezing or rhinorrea may occur during drug provocation tests [78] [79]. Therefore, these procedures should not be generally conducted during the current pandemic [79]. Nevertheless, exceptions can be considered after a proper risk-benefit assessment. Examples of these include chemotherapy in oncologic patients,
perioperative drugs or radiocontrast media in subjects needing urgent procedures, or antibiotics in infected individuals without any alternative effective drug [80] [81].

**Oral food challenges and esophageal examination**

Oral food challenge may induce respiratory symptoms with aerosol-generating potential, together with vomiting and diarrhoea [82]. Importantly, the virus can persist in gastrointestinal fluids for a longer period than in the respiratory specimens [83]. Therefore, oral food challenges should be avoided during the current pandemic, as they lack urgency [84]. The diagnosis of eosinophilic esophagitis requires a gastroscopy-guided esophageal biopsy [85]. The performance of a gastroscopy is not recommended during the current pandemic, due to the possible persistence of virus in biological fluids [86]. In the case of extreme need (e.g. frequent food impaction), a proper risk-benefit assessment should be conducted [87].

**Conclusions:** Specific considerations in a clinical setting are necessary for the diagnostic procedures of different allergic diseases during the current pandemic. As SARS-CoV-2 spreads primarily through respiratory aerosols, airways but also other allergy-related organs are affected and preventive measures should be ensured. These comprise ENT exams (including endoscopy), bronchoscopy, nasal or bronchial allergen provocation tests, tissue-sampling, lung function tests, skin testing and blood-sample collection, drug provocation tests, oral food challenges and esophageal exams.

VII. Specific considerations in the management of different allergic diseases

**General treatment recommendations for selected allergic diseases during COVID-19**

According to WHO, patients at risk of or with diagnosed COVID-19 should continue their treatment for any other disease (this includes allergic disease) in line with current guidelines. Special consideration should be given to the interference of drugs with COVID-19 or vice versa [25]. It is generally recommended that patients should have a supply of the medication they need for at least a 14-day quarantine. Where more stringent or lengthy measures of isolation are enforced, consideration must be given to availability of medicines and potential substitutes for current
treatments if particular medications cannot be obtained. Patients should have an action plan to ensure that these issues are covered.

Telemedicine visits cannot replace all personal consultations, notably those mandatory for the administration of subcutaneous allergen immunotherapy (SCIT). Nevertheless, prior to the consultation, questions identifying actual contraindications can be clarified by a telemedicine consultation. Many of the biologics used for the treatment of allergic diseases (e.g. Omalizumab, Benralizumab, Mepolizumab and Dupilumab) are registered for self-application if the patients are adequately trained in the injection technique and in the assessment and management of allergic side effects. During telemedicine visits, injection techniques may be rechecked, and patients’ questions answered regarding the treatment. Peak flow protocols can be discussed during a telemedicine visit, and treatments can be adapted.

In general, patients can be instructed on allergen avoidance measures and treatment modalities. They can show the drugs they have at home, and can be instructed on the use and especially on the application techniques of inhalers and topical nasal sprays. Patients suffering from anaphylaxis may be trained to use adrenaline auto-injectors for self-administration; this improves safety and may also improve the patient’s quality of life.

As a general rule, patients with severe allergic disease who are on biologicals and have a SARS-CoV-2 infection should pause the biologicals. Proper management and background controller treatment (topical steroids or other controller medications as recommended by current guidelines) should be continued as prescribed. If resolution of the disease is established (e.g. via a negative SARS-CoV-2 test) at a minimum of 2 weeks post onset/positive testing, the re-administration of the biological should be re-initiated [9].

Avoidance measures

Importantly, self-identified and physician-diagnosed (via skin prick test, blood test, provocation testing) triggers of asthma exacerbation and allergies (seasonal, food allergies, etc.) need to be understood for each patient. Targeted messages to
patients who have a known allergen sensitivity may be a meaningful way of connecting with patients during a time of limited in-person clinic visits (e.g. reminder alerts that the spring season has arrived). Educational outreach messages or tele-visits can include instructions on allergen avoidance, indoor air purifiers, proper medication use (e.g. reviewing the appropriate use of inhalers with spacers). Food scarcity during pandemic operations may adversely impact food-allergic families and strategies for planning and stocking safe foods should be discussed. Medication supply should also be addressed in conversations with patients to plan for adequate controller and rescue medication with the possibility of substituting or switching medications as needed.

COVID-19 in the light of different allergic diseases

The following section overviews recommendations for selected allergic diseases (Table 4):

| Disease                      | Recommendations for COVID-19-diagnosed individuals or for cases with suspected SARS-CoV-2 infection | Recommendations for noninfected individuals during the COVID-19 pandemic or for patients having recovered from COVID-19 infection |
|------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Allergic rhinoconjunctivitis | - Continue INCS
- Continue second-generation H1-antihistamines
- Stop SCIT until resolution of the disease is established
- Stop SLIT until resolution of the disease is established
- biologicals * | - Continue INCS
- Continue second-generation H1-antihistamines
- Continue SCIT and SLIT
- Consider supplying patient with a sufficient amount of SLIT medication for home self-administration (for a 14-day quarantine at least) |

- biologicals *

| Asthma                       | - For severe attacks, pressurized metered dose | - Continue all inhaled medication, including ICS |
|------------------------------|------------------------------------------------|--------------------------------------------------|
| Inhaler (pMDI) via a spacer is the preferred treatment instead of nebulizers |
|---|
| While a patient is being treated for a severe asthma attack, their maintenance inhaled asthma treatment should be continued (at home and at hospital) |
| For acute asthma attacks, patients should take a short course of oral corticosteroids (if instructed in their asthma action plan or by their healthcare provider), to prevent serious consequences. |
| Additional treatment should be based on the individual patient and on the underlying disease. |
| - biologicals * |
| (containing therapies), as prescribed by the physician and in line with the personal asthma action plan. |
| - If needed, OCS should be continued at the lowest possible dose in patients at risk of severe attacks/exacerbations. |
| - Routine spirometry testing should be suspended to reduce the risk of viral transmission, and, if absolutely necessary, adequate infection control measures should be taken. |
| - biologicals * |

| Atopic dermatitis |
|---|
| - Continue topical treatment |
| - Systemic immune-modulating therapy may be paused based on interdisciplinary risk assessment. Optimize the topical treatment after pausing systemic treatment. |
| - biologicals * |

| Chronic Rhinosinusitis [11] |
|---|
| - Like in other upper airway viral infections (common cold or flu), the loss of smell is a frequent symptom in COVID-19 patients. But a sudden and severe loss of smell (anosmia) and/or taste may also be |
| - Anosmia in COVID-19 patients often improves within 14 days |
| - Patients with CRS should continue using their INCS |
| Drug Allergy [89] | Present in COVID-19 patients who are otherwise asymptomatic [62] [59] |
|------------------|---------------------------------------------------------------------|
|                   | - Surgery for CRS should be avoided unless patients are proven COVID-19 negative |
|                   | - Patients with CRS should continue using their INCS biologicals * |
|                   | - Biologicals * |
|                   | Quick and accurate diagnostic and therapeutic decisions are mandatory in the case of DHRs induced by COVID-19 drugs. |
|                   | Severe allergic reactions must be treated immediately. Diagnostic testing may be urgently indicated in the case of suspicion of allergic reaction to highly necessary drugs. |
|                   | When validated and reliable, in vitro test may be preferred for diagnosis. If not immediately required, drug allergy diagnostic must be postponed until pandemic is locally under control, and alternative drugs should be used until then. |

| Food allergy | Severe allergic reactions must be treated immediately. Diagnostic testing should be postponed. In vitro diagnostic tests can be preferred for diagnosis in severe anaphylaxis cases. |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|              | Strict avoidance measures must be taken and an adrenalin |
|              | Severe allergic reactions must be treated immediately. Diagnostic testing should be postponed. In vitro diagnostic tests can be preferred for diagnosis in severe anaphylaxis cases. |
|              | Strict avoidance measures must be taken and an adrenalin |
| Condition                  | Recommendations                                                                 |
|----------------------------|---------------------------------------------------------------------------------|
| Venom allergy              | **Severe allergic reactions must be treated immediately.**                        |
|                            | **Diagnostic testing is postponed.**                                             |
|                            | **Strict avoidance measures must be taken and an adrenalin auto-injector must be carried.** |
|                            | - Stop SCIT until resolution of the disease is established.                      |
| Urticaria                  | **- Continue second-generation H1-antihistamines.**                              |
|                            | **- Systemic immune-modulating therapy may be paused based on interdisciplinary risk assessment.** |
|                            | **- biologicals**                                                                |
|                            | **Mastocytosis and grade 3 or 4 anaphylaxis patients need to be diagnosed and venom IT initiated.** |
|                            | **Strict avoidance measures must be taken and an adrenalin auto-injector must be carried.** |
|                            | - Continue SCIT.                                                                 |

**Biologicals**

**Recommendations for COVID-19-diagnosed individuals or for cases with suspected SARS-CoV-2 infection**

- Stop until resolution of the disease is established (e.g. via a negative SARS-CoV-2 test in connection with clinical recovery), but for a minimum of 2 weeks from

**Recommendations for noninfected individuals during the COVID-19 pandemic or for patients having recovered from COVID-19 infection**

- Continue the application of biologicals - if possible as home self-administration.

This article is protected by copyright. All rights reserved
Table 4: Key-recommendations from recently-published EAACI- / ARIA-statements. These recommendations are conditional and should be adapted regularly on the basis of more clinical data. epicutaneous immunotherapy (EPIT); CRS, chronic rhinosinusitis; INCS, intranasal corticosteroids; OCS, Oral corticosteroids, OIT, oral immunotherapy; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy

Atopic Dermatitis

Atopic dermatitis is one of the most common skin disorders. The lifetime prevalence varies between 0.2% and 25% worldwide, the most effected area being the northern part of Europe [90]. The disease most often starts in early childhood and persists into adult life in up to 50% of affected patients [91]. Co-morbidities with other atopic diseases including asthma, allergic rhinitis and food allergy are common [92]. Most with mild to moderate atopic dermatitis can be controlled on topical treatment. However, in the severe cases, systemic immune-modulating treatments including immuno-suppressive therapy is needed [93]. Conventional systemic immuno-suppressive treatment, such as Ciclosporin, may interact with the human body’s defense mechanisms against viral disease, while Dupilumab, which is registered in many countries for the treatment of moderate to severe atopic dermatitis, selectively interferes with type 2 inflammation and is in general not considered to increase the risk for viral infections.

It is well known that viral and bacterial infection may complicate and exacerbate atopic dermatitis including infections with Staphylococcus aureus (impetigo), poxvirus (molluscum contagiosum) and Herpes Simplex virus (eczema herpeticum) [92]. Severe and untreated atopic dermatitis is a known risk factor for disseminated viral skin disease [94].

In the current SARS-CoV-2 pandemic, the European Task Force on Atopic Dermatitis (ETFAD) recommends to continue all immune-modulating treatment since exacerbations of underlying diseases can have a large negative impact on the patient’s immunity [30]. However, patients at risk are advised to strictly follow the recommendations issued by the local health authorities in each European country.
The British Association of Dermatologists (BAD) has addressed potential issues regarding the COVID-19 infection of patients undergoing immune-modulating treatment [95]. Other countries will follow. A thorough hygienic procedure is recommended with hand washing and disinfectants. Non-irritant soap substitutes should be used following the same instructions as those for regular soap. Moisturizers should be applied afterwards. In the case of COVID-19-infected atopic dermatitis patients, interdisciplinary risk assessment should be carried out and, in accordance with current guidelines on active infections and systemic therapy, the immune-modulating therapy may or may not be paused afterwards [30]. If systemic treatment is paused, it is important to optimize the topical treatment. Furthermore, if the paused systemic treatment also has an effect on co-morbidity such as asthma, then the co-morbidity also has to be treated by other drugs. According to a letter from Italy regarding 245 patients on therapy with Dupilumab, only two developed COVID-19 [96]. An abnormal course of COVID-19 was not observed in these 2 patients. More clinical data are needed for this specific treatment.

Urticaria

Urticaria is characterized by the development of wheals (hives), angioedema or both [97]. Acute urticaria is defined as the occurrence of wheals, angioedema or both for less than 6 weeks. Chronic urticaria is defined as wheals, angioedema or both for 6 weeks or more [97]. Viral infection has been found as a potential trigger - and sometimes as the main etiologic agent - in causing acute or chronic urticaria [98].

In Italy, 88 patients with COVID-19 were studied by a group of dermatologists. 20% developed cutaneous symptoms including erythematous rash and urticaria. It was concluded that the skin manifestations related to the COVID-19 infection are similar to those occurring during common viral infections [99]. In France, among 103 out- and in-patients with confirmed COVID-19 infection, two had urticaria [100]. In a study from China, 1.4% of the COVID-19 patients reported an underlying urticaria. However, skin symptoms during the infection were not described [5]. The manifestation of urticaria could appear before the onset of fever or respiratory symptoms [101].
As a consequence of these observations, the manifestation of acute urticaria could be an indication to test for SARS-CoV-2. According to the guidelines, second-generation H1-antihistamines are the base of urticaria treatment [97] and should be continued during the pandemic. If urticaria cannot be controlled on antihistamines in four-fold dose, Omalizumab is recommended as an add-on treatment. Omalizumab is registered for self-administration after patients have received training on the injection technique and on the assessment of allergic side effects. Only the first two injections need to be administered in hospital, due to the risk of anaphylaxis. Therefore, especially during the COVID pandemic, treatment at home is favourable. By telemedical visits, the efficacy of the treatment can be evaluated and patients’ questions regarding the treatment may be reviewed. This is currently recommended by the BAD [95]. As for all COVID-19 infected patients, interdisciplinary risk assessment should be performed and, in accordance with current guidelines on active infections and systemic therapy, the immune-modulating therapy may or may not be paused afterwards.

Food Allergy

Many reactions to foods are mild-moderate and can be self managed by the patient, given the availability of an up-to-date action plan and adequate rescue medication. During periods of isolation, it is vital that children and adults with food allergy have access to suitable foods according to their dietary recommendations [102]. Patients with a history of severe anaphylactic reaction urgently need an emergency health card providing information on the diagnosis, eliciting (causative) allergens, and necessary treatment in the case of a severe reaction and / or an unexpected hospital admission due to COVID-19 [103]. Oral (OIT) and epicutaneous immunotherapy (EPIT) for Food Allergy should follow the general rules of EAACI/ARIA for AIT during COVID-19 pandemic (description in subchapter “allergic rhinoconjunctivitis”).

Venom allergy

In the case of an anaphylactic reaction due to an actual insect sting, patients should be treated according to the guidelines. Especially in high-risk patients (e.g. high risk for subsequent stings, patient suffering from mastocytosis, patient with
grade 3 or 4 anaphylaxis), the diagnosis of insect venom allergy must be proved urgently. Venom immunotherapy should be initiated without any delay in order to prevent severe reactions in the case of further stings in the future [104]. The treatment should follow the general rules of EAACI/ARIA for AIT during COVID-19 pandemic (description in subchapter “allergic rhinoconjunctivitis”). Patients must be informed regarding avoidance strategies and provided with drugs for self-administration. Adrenaline autoinjectors must be prescribed, and patients must be trained to use these devices. Prior to the initiation of venom immunotherapy, contraindications and requirements for treatment can be discussed with the patient in a telemedicine consultation.

Drug allergy

Severe allergic reactions to drugs must be treated immediately. Diagnostic testing may be urgently indicated in the case of a suspicion of allergic reaction to highly necessary drugs. This may be the case for example in patients suffering from reactions to antibiotics which may be necessary to treat bacterial superinfection in COVID-19 pneumonia. In the case of an immediate need for treatment with a drug that is suspected to be responsible for systemic allergic reactions, drug desensitization is a therapeutic procedure whose aim is to induce a temporary state of unresponsiveness to a drug in a patient with confirmed allergy. During drug desensitization, respiratory and gastrointestinal symptoms occur commonly [105] [106] with a subsequent risk of spreading infectious aerosols. Therefore, the decision to conduct the procedure during the current pandemic must consider both the expected benefits obtained from the drug administration, as well as the potential risks of severe reaction and infection spread [89]. Absolute indications for desensitization may include chemotherapeutic agents in oncologic patients, aspirin in subjects with ischemic diseases and antibiotics in infected individuals when no effective alternative is available [107].

Chronic rhinosinusitis

Chronic rhinosinusitis (CRS) affects approximately 5-12% of the general population worldwide and is regarded as a chronic airway disease, that, according to WHO recommendations, may be a risk factor for COVID-19 patients [6] [11].
inflammatory changes affecting the nasal and paranasal mucous membranes in CRS with nasal polyps (CRSwNP) are, in most cases, of the type 2 (T2) inflammation endotype. They are typically associated with epithelial damage and tissue destruction [108], which can promote viral infections [109]. Asthma often coexists with CRSwNP and it is known that deterioration in the control of CRSwNP can promote asthma exacerbations [109].

Symptoms of nasal obstruction, rhinorrhea, facial pressure and smell problems regularly occur in CRS. Recently, a number of reports have been indicating that a sudden and severe (anosmia) isolated onset of loss of smell (ISOA) and/or loss of taste may also be present in COVID-19 patients who are otherwise asymptomatic. This is considered a marker symptom in screening for SARS CoV-2 infection [110] [111] [62], but may also interfere with loss of smell in CRS [11]. CRS is treated with intranasal corticosteroids (INCS), systemic corticosteroids or specific, T2 endotype-driven anti-inflammatory therapies according to the severity of disease [112]. INCS remain the standard treatment for CRS in the COVID-19 pandemic and also for patients with SARS-CoV-2 infection [11]. Surgical treatments should be reduced to a minimum and surgery should be preserved only for patients with local complications and those for whom no other treatment options exists. Systemic corticosteroids should be avoided. Treatment of severe uncontrolled CRSwNP patients [112] with biologicals can be continued with careful monitoring in non-infected patients. However, it should be temporarily discontinued in patients having tested positive for SARS-CoV-2 (RT-PCR), until recovery. We suggest that physicians assess the risks vs. benefits in low-risk patients before initiating biologics therapy on a case-by-case basis. However, it should not be initiated in high-risk patients [11] [9].

Allergic rhinoconjunctivitis

There have been reports that topical applied "corticosteroid preparations" may increase the risk of developing COVID-19 or may cause a more severe course of the disease. This opinion massively unsettled numerous patients suffering from allergic rhinitis (AR), CRS or asthma. A current Position Paper by ARIA and EAACI on AR treatment [88] states that INCS are the therapeutic standard for the treatment of AR regardless of symptoms and inflammation, thus avoiding mucosal damage. In approved doses (see package leaflet), INCS do not increase the risk of infections in
patients with SARS-CoV-2, nor do they trigger a more severe course of COVID-19 disease [88]. Reducing allergic mucosal inflammation by INCS may even shorten the duration and decrease the severity of symptoms in upper respiratory tract virus infections of AR patients [113], but seems not to have any marked effects on the common cold symptoms of patients without AR. Therefore, it is recommended that patients with AR should continue to regularly use their INCS at the individually-prescribed dose. Hence, it is not advised that they change or even stop their treatment without consulting their doctor [88]. Discontinuation of INCS may worsen AR symptoms with increased secretion and sneezing which may promote viral droplet transmission from SARS-CoV-2 infected patients to healthy individuals [88]. In addition, worsening of AR can trigger an exacerbation of asthma [88], which is regarded by WHO as a risk factor for severe courses of COVID-19. Systemic glucocorticosteroids in general have several adverse effects if given long term [114]. For AR, they should be used with even more caution during the current COVID-19 pandemic and only when no therapeutic alternatives are available [88] because of a potential temporary immunosuppression and a possible increased risk of contracting a SARS-CoV-2 infection or progression to severe disease [114].

Allergen immunotherapy (AIT) is the only disease-modifying treatment option for patients with allergic diseases as applied through the subcutaneous (SCIT) or sublingual route (SLIT) [115] [116]. During the current pandemic, special considerations should be introduced to the management of AIT [117] [10]. All in-person consultation may be preceded and prepared by a telemedicine visit, during which information is obtained about the patient’s health status and possible contraindications for AIT. Since SLIT is self-administered at home during the maintenance phase, telemedicine visits may be helpful for advising patients and increasing their adherence to treatment.

In noninfected individuals during the COVID-19 pandemic or in patients having recovered from COVID-19 infection, it is recommended to continue SCIT in potentially life-threatening allergies, such as venom allergy [10]. The possibility of expanding injection intervals in the continuation phase should be evaluated and may be beneficial. SLIT should also be continued, and the patient must be supplied with sufficient medication.

For both application routes a continuation of AIT is possible in principle under the following prerequisites [10]: (i) asymptomatic patients without suspicion of SARS-
CoV-2 infection and/or contact with SARS-CoV-2 positive individuals, (ii) patients with a negative test result (RT-PCR), (iii) patients after an adequate quarantine or (iv) patients with detection of serum IgG to SARS-CoV 2 without virus-specific IgM. In COVID-19-diagnosed cases (positive RT-PCR), in patients suspected of SARS-CoV-2 infection, or in symptomatic patients with exposure or contact to SARS-CoV-2-positive individuals, EAACI recommends interrupting SCIT and SLIT until recovery [10].

If AIT is stopped due to signs of a potential SARS-CoV-2 infection (such as fever, cough, dyspnea), or due to other signs of ill health, or due to local restrictions on clinic operations, it should be resumed after recovery but with proper dosage adjustment and under medical supervision when appropriate. To maintain social distancing procedures in the clinic, the following methods could be considered: stretching out the interval of IT or organizing different clinic hours to limit the number of patients attending for IT [10] [118].

Asthma

To date, there is very little information available on patients with asthma who have COVID-19. In general, viruses, including rhinoviruses and respiratory syncytial viruses, have been shown to induce asthma episodes or exacerbations [119] [120]. Mounting evidence implicates that particular viral pathogens, namely the human rhinovirus and respiratory syncytial virus, are among the most likely culprits in asthma inception [120]. Bacterial infections and colonization have also been associated with exacerbation and recurrent wheeze, an effect that may be independent, or a cofactor with viruses. In addition, certain individuals may have a genetic predisposition towards viral-induced wheezing and the development of asthma [120]. Whether this also applies to SARS-CoV-2 infection remains to be seen. Interestingly, according to initial reports, allergic airway disease including asthma did not appear to be a risk factor for COVID-19 or for a severe clinical course [5] [8] [121]. However, more recent reports from the USA show asthma as an underlying condition in 13-27% of patients hospitalized with COVID-19, within the COVID-NET hospitals [33]. Additionally, immunocompromised patients - including the elderly, those with diabetes mellitus or those on (systemic)
corticosteroids in conjunction with the underlying immune disorders - may be at an increased risk of being infected and more severely affected by SARS-CoV-2 [5] [122].

Optimal disease control is the first defense against respiratory triggers including infections in patients with inflammatory airway disease such as allergic rhinitis and asthma. Inhaled maintenance therapy with bronchodilators and ICS should not be stopped during the COVID-19 pandemic [13]. The termination of inhaled treatment may in fact imply an increased risk for asthma symptom worsening and acute airway exacerbations. Furthermore, the risk of asthma deteriorating in a threatening manner and necessitating (otherwise unscheduled) doctor visits or hospital stays - potentially responsible for contact with COVID-19 patients - is far more dangerous for asthmatic patients than a possible increased risk of SARS-Cov-2 infection due to a theoretic local immunodepression induced by ICS. Given the lack of current evidence that ICS negatively affect the COVID-19 outcome, experts and professional societies within the respiratory and allergy field - including the Global Initiative on Asthma (GINA), the American Academy of Allergy, Asthma and Immunology (AAAAI), the European Respiratory Society (ERS) and EAACI - all stress the importance of disease control, especially since many countries are now entering the spring pollen season [13]. Apart from the generally applicable avoidance measures issued by the governments, the societies recommend that patients continue taking their corticosteroid-containing controller medications and other controllers (including biologicals), as detailed in their personal asthma plan and that they should seek medical help if disease control deteriorates [88] [123] [124] [125] [126]. This applies both for adults and children with chronic inflammatory airway disease and for with COVID-19 or a suspicion of having the infection. Contact with health care providers should be digital as much as possible.

Treatment of severe asthma with biologicals should also be continued [9]. A discontinuation of biologicals can lead to a worsening of the underlying disease, which in turn could have a negative impact on the course of a COVID-19 infection [9]. Virus-related asthma exacerbations occur less frequently or are less severe under biologicals, as demonstrated for Omalizumab, but not in the context of COVID-19 [127] [128]. However, when authorized by international regulatory bodies (i.e. the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA)), self-administration should always be advised in order to
reduce exposure to high-risk environments such as hospitals and primary care settings.

In the absence of biological therapy, patients would have to be switched to therapy with systemic glucocorticosteroids, especially those with severe asthma. This can have negative effects on the immune defense against SARS-CoV-2. In a study performed on patients from the Seattle area, severe respiratory failure was observed in 3 of 24 COVID-19 patients after systemic glucocorticoid treatment due to asthma exacerbation [32].

Post-COVID-19 routine care
For patients who have recovered from moderate to severe COVID-19 infection, particular attention should focus on lung, kidney, cardial and liver recovery before re-instituting usual medications [129] [130] [131] [132] (Figure 3). Some patients infected with SARS-CoV-2 have a severe systemic inflammatory response, with marked elevation in CRP, d-dimer, and ESR in addition to multi-organ dysfunction. Patients may have participated in COVID-19 clinical trials and it is important to note which medication was potentially administered (see section “Considerations for performing clinical trials”). When resuming allergy care, clinical judgement should determine whether additional labs (complete blood count, liver function test, kidney function) or lung function testing are necessary before restarting the treatment of allergic diseases and this decision should be based on a multidisciplinary consultation. In some cases, a close follow-up to assess pulmonary rehabilitation may be warranted.

Conclusions: Though avoidance measures during the COVID-19 pandemic are similar in different allergic diseases, specific aspects should also be followed in optimal care for allergic rhinoconjunctivitis, asthma, atopic dermatitis, chronic rhinosinusitis, drug allergy, food allergy, urticaria and venom allergy. Different
recommendations can be provided for patients with suspected SARS-CoV-2 infection or diagnosed COVID-19 disease versus noninfected individuals or patients having recovered from COVID-19 infection.

After recovery from COVID-19, allergy care has to be resumed, but an interdisciplinary consultation is recommended before any further diagnostic or therapeutic procedure.

VIII. Socio-psychological considerations for allergic patients and optimal care during and after the pandemic

Allergic responses are affected by psychological factors such as stress and anxiety and can be modulated by interventions other than conventional drug therapy [133]. These psychological mechanisms play a role in terms of symptom development, symptom exacerbation and perception [134, 135]. The reactions of other people to patients showing allergic respiratory symptoms during the COVID-19 pandemic are amplified. These reactions, along with the governmental regulations (e.g., social distancing) for dealing with the pandemic, induce further stigmatization and thus enhance psychosocial stress for allergic patients.

Symptom development and symptom perception are only partially caused by the biological mechanisms of the allergy, and many patients report bodily symptoms that are mainly developed via psychological effects (nocebo effects). Relevant psychological mechanisms for symptom development include: negative expectations, increased self-observation of somatic reactions, catastrophizing of perceived symptom (dysfunctional appraisal), as well as fears and negative affect [136]. For many patients (and sometimes even for their physician), the reported symptoms are a conglomerate of potential allergic symptoms, potential symptoms of COVID-19, and correlates of concern that are almost impossible to disentangle. These nocebo symptoms can account for up to 80% of patients with medical conditions [137].

During the COVID-19 pandemic, the general population is highly sensitive to the perception of people showing respiratory symptoms. This increases the risk of stigmatization of patients with allergies, further increasing the psychosocial stress...
of the patients. The neuroendocrine and immunological consequences of stress exposure are in turn able to amplify the development of allergic symptoms [134] [138]. Negative effects on the willingness to expose oneself to those contacts (e.g. at work, in private social networks) are further potential consequences with negative impact on health conditions. This is even more problematic, because social contact and social support can dampen negative stress effects and reduce disease symptoms [139]. Several recommendations to improve medical care for patients with allergies during the COVID-19 pandemic can be given (Table 5).

- Manage the increased potential for the development of nocebo symptoms: patients should be informed about the potential detrimental effects of nocebo mechanisms, such as increased self-observation or negative expectations. Patients should be encouraged to work against them, and to disentangle stress effects from symptoms of clinical conditions.

- Despite public encouragement for social distancing and increased social stigmatization in the public, patients should be encouraged to maintain an active social network employing the available communication channels. Social support is a crucial factor for improving health in general.

- Encourage patients to do regular physical exercise. Regular physical activities induce anti-inflammatory responses.

- An empathetic, reliable and predictable doctor-patient relationship guarantees patient compliance with medical recommendations and lowers nocebo effects.

- Encourage engagement in stress reduction activities such as relaxation techniques, mindfulness, yoga.

| Table 5: improving medical care for patients with allergies during the COVID-19 pandemic |
|---|
| Conclusions: Socio-psychological mechanisms play a major role in terms of symptom development, symptom exacerbation and perception in allergic patients. Besides, the general population is highly sensitive to the perception of people showing respiratory symptoms during the COVID-19 pandemic. This increases the risk of stigmatization of patients with allergies, further increasing the psychosocial stress of patients. Therefore, optimal medical and psychological care for patients with allergies during the COVID-19 pandemic is essential. |

This article is protected by copyright. All rights reserved
IX. Considerations for performing non-COVID-19-related clinical trials

Many of the ongoing non-COVID-19-related clinical trials have been suspended during the current COVID-19 pandemic for safety and feasibility reasons as recommended by guidance from the US Food and Drug Agency as well as the European Medicines Agency [140] [141]. While it is imperative that clinical trials on COVID-19 be prioritized and quickly implemented following local regulatory policies and fulfilling highest quality standards [142] [143], it is also critical that other essential clinical research programmes, such as those involving study drugs or clinical assessments, should safely continue as much as possible. However, the social distancing measures put into place by different governments (e.g. close-down of clinical units and public transportation, etc.) complicate the implementation of certain protocol-related procedures, scheduled visits, or hospital / clinic procurement of study medication. Nevertheless, with proper adjustments, some studies can be continued safely without loss of data integrity. In the following, we discuss safety and regulatory measures as well as logistical issues that should be taken into consideration when amending non-COVID-19 related clinical trial protocols during the COVID-19 pandemic (Table 6).

- Provide written and oral instructions on disease symptoms and signs and for the prevention of disease spread.

- Study participants, research and laboratory staff may need to monitor their temperature and check for symptoms and signs of the pandemic during participation in the trial and if entering the clinical research unit/workplace.

- Study participants, research and laboratory staff should frequently wash their hands with disinfectants, wear PPE (e.g., laboratory garments, gloves, face masks, eye protection), and clean work surfaces and equipment with appropriate disinfectants.

- Consider which visits can be conducted via remote solutions (phone check-ups, tele-consulting and monitoring) [36].

- Provide specific instructions on clinical trial unit procedures, particularly those that generate aerosols/droplets (e.g., sputum and nasal fluid collection, nasal and bronchial provocation testing). All isolations of peripheral blood mononuclear cells (PBMC) and bronchoalveolar
lavages (BAL) should be performed in a BSL2 bench. For centrifugation steps, the use of closed beakers should be mandatory.

- Provide specific instructions for the collecting, handling and processing/testing of specimens from clinical trial participants.

Table 6: General consideration when amending non-COVID-19 related clinical trial protocols during the COVID-19 pandemic

Immediate contact is indicated with all involved parties - sponsor, institutional review board (IRB), institutional ethics committee (IEC), participants, investigators and staff - as well as with all enrolled participants, to inform them of the changes related to the pandemic. All immediate actions should take place as long as the pandemic-related policies are in place and documented. Otherwise, conventional amendments are required.

Essential non-COVID-19-related research can be continued safely during the COVID-19 pandemic while maintaining data integrity with appropriate amendments to the protocols. These adjustments should take into consideration modern technological communication tools (between hospital staff and patients), IP delivery, appropriate laboratory safety guidelines, and proper source (case report form (CRF)), statistical analysis plan and regulatory documentation (Figure 4).

INSERT: Figure 4 here

Figure 4: Ensuring data integrity in non-COVID-19-related research

Participant interactions:
In conducting non-COVID-19-related trials (i.e., in apparently non-infected individuals), the safety and well-being of the participants and hospital and research staff during physical interactions and specimen handling should be considered and risks evaluated. When possible and appropriate, remote options for participant visits using telemedicine or video consulting may facilitate the conduct of the clinical trial. Contact scripts to standardize messages are recommended. In general, these scripts do not require approval during lockdown. Study procedures that generate aerosols or droplets, such as spirometry or nebulization of agents or
medication, may require special considerations on how to perform similar assessments safely or may need to be reconsidered. Staffing considerations should include the minimal essential personnel required to carry out study visits, and staff should be cross-trained and added to Delegation of Authority logs, as appropriate.

Regulatory guidance
Regulatory aspects of protocol amendments need to be considered [140, 141]. Changes to protocols after Institutional Review Board (IRB) approval are only allowed without prior approval in cases where there is a need to eliminate immediate hazards for the participants. Regulations allow protocol adjustments for participant safety and minimization of risks for data integrity in line with good clinical practice (GCP). In light of the COVID-19 pandemic, certain study visits or procedures may need to be paused or re-designed. This could facilitate ongoing research while maintaining safety and also allow time for evaluating the benefits of continuing investigational products for enrolled participants versus the disadvantages (harm incurred) of discontinuing. New strategies for safety assessments, monitoring, and data collection should be considered. Proper and detailed documentation of updates to procedures and operations is critical and protocol amendments should be communicated to research staff, participants, sponsors and regulatory agencies as soon as possible. Changes that may impact efficacy assessments, data management and/or statistical analysis plans should be discussed, when necessary, with the appropriate EMA-/FDA-division review. Records of all deferred procedures need to be kept and documented.

Investigational Product
Depending on the clinical trial, adjustments to investigational product (IP) administration may be possible with the use of telemedicine. These decisions must involve conversations with protocol chairs, sponsors, medical monitors and regulatory authorities as applicable. If participants are not able to come into the Clinical Research Unit (CRU), other options to continue IP intake include curb-side dispensing or direct shipping of pharmaceuticals. The research pharmacy staff should ensure that all local and federal regulations are followed with regards to the documentation and transport of study medication. In parallel, any necessary rescue medications should be provided to study participants, and documented with
prior communication to relevant parties. Further guidance for the investigational product should be followed (table 7).

- Treatment initiation and dose increases only performed in clinic; levels maintained at a stable dosage (e.g. for oral immunotherapy) when clinic visits not possible
- Training of at-home administration of biologics and injectables, where applicable [9]
- Ensuring participants maintain adequate IP supply to continue at-home dosing as needed without disclosing identity via research pharmacy (direct-to-participant shipments or curbside dispensing)
- Ensuring integrity between pharmacy and participant in the case of shipping (secure chain of custody and monitoring of storage conditions in transit)
- Necessary rescue medication provision with written instructions and emergency phone numbers

Table 7: General consideration on investigational products when performing a non-COVID-19-related clinical trial during the COVID-19 pandemic

Laboratory safety and precautions

Laboratory staff should follow Standard Precautions (SP) when handling clinical specimens, all of which may contain potentially infectious materials (see also section v) [71]). SP include hand hygiene and the use of PPE, such as laboratory coats or gowns, gloves and eye protection. All new arriving samples can be potentially infected. Isolations have to be performed with closed centrifuge beakers which will be loaded and unloaded under the biosafety cabinet. Material carriage should be performed with aerosol tight transport boxes. The usage of BSL2 benches for all arriving patient material is mandatory during and after the pandemic times. Handling of open vessels may only be performed inside of class II biosafety cabinets.

Antibody tests and procedures that utilize samples that are formaldehyde fixed or virus-inactivated, or those that concentrate viruses (via precipitation or membrane filtration), may be performed in a Biosafety Level 2 (BSL-2) laboratory. BSL-3 facilities and procedures are recommended for virus isolation in cell culture, initial characterization of viral agents recovered in cultures of SARS-CoV-2 specimens, and
virus neutralizing antibody assays (Table 8). All work surfaces and equipment should be decontaminated with appropriate disinfectants.

| Biosafety level 2 (BSL-2) precautions | Biosafety level 3 (BSL-3) precautions |
|--------------------------------------|--------------------------------------|
| o Flow cytometry of formaldehyde-fixed specimens | o Procedures with human or animal primary specimens to intentionally concentrate or isolate SARS-CoV-2 for research purposes (e.g., ultracentrifugation of a sample) |
| o Cell sorting with FACS Sorter has to be performed in the closed tube system. If a plate sort is necessary, the aerosol protection has to be used | o Culturing specimens (e.g., propagated virus) |
| o Assays with virus inactivated specimens | o Preparatory work for in vivo activities |
| o Concentration of samples prior to inactivation | o Processing a culture (i.e., propagated or cultivated) known to contain SARS-CoV-2 for packaging and distribution to laboratories |
| o Sample preparation for nucleic acid extraction, flow cytometry analysis, molecular testing of nucleic acids | o Preparing inoculum, inoculating animals, and collecting specimens from experimentally infected animals. |
| o Antigen and antibody assays | o Virus neutralization tests for blocking activity against SARS-CoV-2 (with live virus) |

Table 8: Laboratory procedures that may require different biosafety level precautions [71]

**Conclusion:** Clinical trials to combat the COVID-19 pandemic currently have top priority. However, a number of non-COVID-19 trials are also essential and should be continued if they can be conducted in a safe manner. Safety measures and new guidelines need to be established for participants, and research/laboratory staff dealing with non-COVID-19 related clinical trials to ensure the continuation of essential and critical non-COVID-19 trials.
Discussion

In view of the ongoing and emerging novel coronavirus (COVID-19) pandemic spreading worldwide [2], the safety and well-being of our patients, personnel, and colleagues globally are of primary importance. EAACI and ARIA are closely monitoring the situation. They recommend aligning any diagnostic and treatment operations with guidance from WHO [25] and ECDC [26], in accordance with all applicable national/regional/local government and public health authority requirements.

Allergists and other health care providers (HCPs) in the field of allergies and associated airway diseases are on the front line in taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks for infection of both HCPs and the treated patients have to be developed and followed by allergy clinics [20]. This is especially important in high-risk patients for the course of a SARS-CoV-2 infection e.g. of older age or with comorbidities.

If patients are diagnosed with COVID-19 or are suspected to have COVID-19, they should follow the local area treatment and quarantine guidance. In general, most medications should be continued [88] [10]. Patients may be unable to attend clinic visits, have examinations and/or receive prescriptions. E-Health and telemedicine can assess the value of specialized treatments, provide education for self-management without the risk of infection [44], and triage patients for urgent in-person consultations. Examples for the latter are diagnostic testing in drug allergy in the case of suspicion of allergic reaction to highly necessary drugs [89] or the application of medication (e.g., SCIT or biologicals) through a HCP.

Clinic staff should keep in contact with the patient preferably through telephone calls or video conferences to maintain awareness of their status in the case of symptom exacerbations. Dispensing a sufficient amount of medication is a way of enabling the patient to self-treat. In treatment with biologicals, the decision to continue or discontinue a treatment should be made on a case-by-case basis by the attending physician, since the safety and efficacy of the mentioned biologicals in COVID-19 patients are currently unknown [9]. Besides, psychological care for patients with allergies during the COVID-19 pandemic is essential.
Non-COVID trials may be able to be continued according to regional regulations. However, special emphasis should continue to be placed on the safety of the participants and research/laboratory staff. The same safety precautions used in clinical routine for aerosol-generating procedures and handling of samples should also be applied in the non-COVID trials.

**Conclusion**

According to WHO and ECDC, patients at risk or with diagnosed COVID-19 should continue to be treated for all other diseases according to current guidelines, if there are no interferences of treatment with COVID-19 or vice versa. Preparedness of the allergy clinic, specialized centre or practice is imperative in order to cope with COVID-19 correctly. The recommendations in this Position Paper are conditional since there is a paucity of data. They should be revised regularly with new incoming information on COVID-19.

As doctors, scientists and specialist societies, we are required to observe our patients, to provide optimal advice and treatment based on the current state of medical knowledge, and to inform them accordingly when new evidence is available, making it possible to adapt the therapies. EAACI has a prevailing requirement to protect the safety and welfare of our patients, allergists and staff and is working diligently to ensure responses to new recommendations as quickly as possible.
References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020; 382: 1199-207.

2. Coronavirus disease (COVID-19) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports, Accessed on 16 Apr 2020.

3. Asthma and Allergy Foundation of America (aafa). https://www.aafa.org/media/2631/respiratory-illness-symptoms-chart-coronavirus-flu-cold-allergies.png. Accessed 12 May 2020.

4. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A, Network C-LI, Nailescu A, Corona A, Zangrillo A, Protti A, Albertin A, Forastieri Molinari A, Lombardo A, Pezzi A, Bennini A, Scandroglio AM, Malara A, Castelli A, Coluccello A, Micucci A, Pesenti A, Sala A, Alberghetti A, Antonini B, Capra C, Troiano C, Roscittane C, Radziankzi D, Chiumello D, Coppini D, Guzzon D, Costantini E, Malpetti E, Zioa E, Catena E, Agosteo E, Beretta E, Boselli E, Storti E, Harizay F, Della Mura F, Lorini FL, Donato Sigurta F, Marino F, Mojoli F, Rasulo F, Grasselli G, Casella G, De Filippi G, Castelli G, Aldegheri G, Gallioli G, Lotti G, Albano G, Landoni G, Marino G, Vitale G, Battista Peregio G, Evasi G, Citerri G, Zanotti G, Natalini G, Merli G, Sforzini I, Biancardi L, Carnevale L, Grazioli L, Cabrini L, Guatterie L, Salvi L, Dei Poli M, Galletti M, Gennina M, Ranucci M, Riccio M, Borelli M, Zambon M, Subert M, Cecconi M, Mazzoni MG, Raimondi M, Panigada M, Belliato M, Bronzini N, Latronico N, Petrucci N, Belgioni N, Tagliabue P, Cortellazzi P, Gnesin P, Grosso P, Gritti P, Perazzo P, Severgnini P, Ruogeri P, Sebastiano P, Covello RD, Fernandez-Olmos R, Fumagalli R, Keim R, Rona R, Valsecchi R, Cattaneo S, Colombo S, Cirri S, Bonazzi S, Greco S, Mutinini S, Langer T, Alaimo V, Viola U, Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020.

5. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD, Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020.

6. WHO. Coronavirus disease (COVID-19) technical guidance: Patient management. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management. Accessed 22 Apr 2020.

7. EAACI Resource Center COVID-19: https://www.eaaci.org/4702. Accessed on 16 Apr 2020.

8. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, Akdis CA, Gao YD, Eleven faces of coronavirus disease 2019. Allergy 2020.

9. Vultaggio A, Agache I, Akdis CA, Akdis M, Bavbek S, Bossios A, Bousquet J, Boyman O, Chaker AM, Chan S, Chatzipetrou A, Feleszko W, Firino D, Jutel M, Kauppi P, Klimek L, Kolios A, Kothari A, Kowlinski ML, Matucci A, Palomares O, Pfaar O, Rogala B, Untersmayr E, Elwegger T, Considerations on Biologicals for Patients with allergic disease in times of the COVID-19 pandemic: an EAACI Statement. Allergy 2020.

10. Klimek L, Jutel M, Akdis C, Bousquet J, Akdis M, Bachert C, Agache I, Ansotegui I, Bedbrook A, Bosnic-Anticevich S, Canonica GW, Chivato T, Cruz AA, Czarlewski W, Giacco SD, Du H, Fonseca JA, Gao Y, Haathela T, Hoffmann-Sommergruber K, Ivanchev JC, Khahtae NV, Knol EF, Kuna P, Larenas-Linnemann D, Melen E, Mullol J, Naclerio R, Ohta K, Okamoto Y, O’Mahoney L, Onorato GL, Papadopoulos NG, Pawankar R, Pfaar O, Samolinski B, Schwarze J,
11. Klimek L, Jutel M, Bousquet J, et al. Treatment of chronic Rhinopathy with nasal polyps (CRSsNP) in the COVID-19 pandemic - An EAACI Position Paper. Allergy 2020 (submitted).

12. Cai Q, Huang D, Ou P, Yu H, Zhu X, Xia Z, Su Y, Ma Z, Zhang Y, Li Z, He Q, Liu L, Fu Y, Chen J, COVID-19 in a designated infectious hospital outside Hubei Province, China. Allergy 2020.

13. Zhang JJ, Cao YY, Dong X, Wang BC, Liao MY, Lin J, Yan YQ, Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2. Allergy 2020.

14. Malipiero G, Paoletti G, Puggioni F, Racca F, Ferri S, Marsala A, Leoncini O, Porli M, Pieri G, Canonica GW, Heffler E, An academic allergy unit during COVID-19 pandemic in Italy. J Allergy Clin Immunol 2020.

15. Beale J, Jayaraman A, Jackson DJ, Macintyre JDR, Edwards MR, Walton RP, Zhu J, Man Ching Y, Shamji B, Edwards M, Westwick J, Cousins DJ, Yi Hwang Y, McKenzie A, Johnston SL, Bartlett NW, Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med 2014;6: 256ra134.

16. Edwards MR, Strong K, Cameron A, Walton RP, Jackson DJ, Johnston SL, Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness. J Allergy Clin Immunol 2017;140: 909-20.
Cristen-Zaech S, Heratizadeh A, Ring J, Vestergaard C, European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infection and atopic dermatitis. J Eur Acad Dermatol Venereol 2020.

31. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, Wang X, Hu C, Ping R, Hu P, Li T, Cao F, Chang C, Hu Q, Jin Y, Xu G, Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. Am J Respir Crit Care Med 2020;201: 1372-79.

32. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger AL, Pipavath S, Wurfel MM, Evans L, Kritek PA, West TE, Luks A, Gerbino A, Dale CR, Goldman JD, O'Mahony S, Mikacenic C, Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med 2020;382: 2012-22.

33. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD, Alden NB, Kawasaki B, Yousef-Hindes K, Niccolai L, Anderson EJ, Openo KP, Weigel A, Monroe ML, Ryan P, Henderson J, Kim S, Comos-Sabetti K, Lynfield R, Sosin D, Torres S, Muse A, Bennett NM, Billing L, Sutton M, West N, Schaffner W, Talbot HK, Aquino G, George A, Budd A, Bramer L, Langley G, Hall AJ, Fry A, Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020;69: 458-64.

34. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, Visness CM, Durham SR, Larson D, Esnault S, Ober C, Gergen PJ, Becker P, Togias A, Gern JE, Altman MC, Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 2020.

35. Waibel KH, Bickel RA, Brown T, Outcomes From a Regional Synchronous Tele-Allergy Service. The journal of allergy and clinical immunology In practice 2019;7: 1017-21.

36. Matricardi PM, Dramburg S, Alvarez-Perea A, Antolin-Amerigo D, Apfelbacher C, Atanaskovic-Markovic M, Berger U, Blaisz W, Blank S, Boni M, Bousquet J, Brockow K, Buters J, Cardona V, Cauquet JC, Cakmakidis G, Chilosi M, Gohlke A, Hoffmann-Sommergruber K, Fusun Karpak-Toluglu A, Marmouz F, Meijide Calderon A, Rosas S, Nakonechna A, Ollert M, Oteros J, Pagno J, Panaiteescu C, Perez-Formigo D, Pfaar O, Pitiot C, Rabe U, Raciti MJ, Saloga J, Schick S, Schilling BM, Schmeil, Christensen C, Sienkiewicz E, Sidenius H, Socrates P, Surati S, Thamboo N, Tversky M, Vasilakos S, Voon CN, Wachtler M, Agache I, The role of mobile health technologies in allergy care: An EAACI position paper. Allergy 2020;75: 259-72.

37. Waller M, Stotler C, Outcomes From a Regional Synchronous Tele-Allergy Service. The journal of allergy and clinical immunology In practice 2019;7: 1017-21.

38. Pereira AM, Jacome C, Almeida R, Fonseca JA, How the Smartphone is Changing Allergy Diagnostics. Curr Allergy Asthma Rep 2018;18: 54.

39. Pereira AM, Jacome C, Almeida R, Fonseca JA, How the Smartphone is Changing Allergy Diagnostics. Curr Allergy Asthma Rep 2018;18: 69.

40. Cuervo-Pardo L, Barcena-Blanch MA, Gonzalez-Estrada A, Schroer B, Apps for food allergy: A critical assessment. The journal of allergy and clinical immunology In practice 2015;3: 980-1 e1.
42. Alvarez-Perea A, Sanchez-Garcia S, Munoz Cano R, Antolín-Amerigo D, Tsilochristou O, Stukus DR, Impact Of “eHealth” in Allergic Diseases and Allergic Patients. J Investig Allergol Clin Immunol 2019;29: 94-102.

43. Portnoy J, Waller M, Elliott T, Telemedicine in the Era of COVID-19. The journal of allergy and clinical immunology In practice 2020;8: 1489-91.

46. https://www.theverge.com/2020/1/28/21082331/zoom-vulnerability-hacker-eavesdrop-security-google-hangouts-skype-checkpoint. Accessed 21 Apr 2020.

51. https://zoom.us. Accessed 21 Apr 2020.

53. https://www.whatsapp.com. Accessed 21 Apr 2020.

54. https://slack.com. Accessed 21 Apr 2020.

56. Xie X, Li Y, Chwang AT, Ho PL, Seto WH, How far droplets can move in indoor environments--revisiting the Wells evaporation-falling curve. Indoor air 2007;17: 211-25.

62. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T, The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg 2020: 194599820926473.

64. Wu Z, McGoogan JM, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020.

65. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J, SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med 2020;382: 1177-79.

66. World Health Organization. Rational Use of Personal Protective Equipment (PPE) for Coronavirus Disease 2019 (COVID-19); 2020. https://apps.who.int/iris/bitstream/handle/10665/331498/WHO-2019-nCoV-IPCPPE_use-2020.2-eng.pdf . Accessed 21 Apr 2020.
67. Tran K, Cimon K, Severn M, Pessoa-Silva C, Conly J, Aerosol-generating procedures and risk of transmission of acute respiratory infections: a systematic review. CADTH Technol Overv 2013;3: e3201.

68. Diamant Z, Gauvreau GM, Cockcroft DW, Boulet LP, Sterk PJ, de Jongh FH, Dahlén B, O’Byrne PM, Inhaled allergen bronchoprovocation tests. J Allergy Clin Immunol 2013;132: 1045-55 e6.

69. Alving K, Diamant Z, Lucas S, Magnussen H, Pavord ID, Placentini G, Price D, Roche N, Sastre J, Thomas M, Usmani O, Bjerner L, Respiratory Effectiveness G, Biomarkers Working G, Point-of-care biomarkers in asthma management: Time to move forward. Allergy 2020;75: 995-97.

70. Meselson M, Droplets and Aerosols in the Transmission of SARS-CoV-2. N Engl J Med 2020;382: 2063.

71. Centers for Disease Control and Prevention. Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19). Available at https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html. Accessed April 19 2020.

72. Practical information from Robert Koch Institute https://www.rki.de/DE/Home/homepage_node.html. Accessed 21 Apr 2020.

73. Practical information from World Health Organization https://www.who.int/. Accessed 21 Apr 2020.

74. Practical information from International Air Transport Association (IATA) https://www.iata.org/en/programs/cargo/dgr/. Accessed 21 Apr 2020.

75. World Health Organization. Guidelines on regulations for the transport of infectious substances 2019-2020. https://apps.who.int/iris/bitstream/handle/10665/325884/WHO-WHE-CPI-2019.20-eng.pdf?ua=1. Accessed 21 Apr 2020.

76. World Health Organization (WHO). GENERAL PROCEDURES FOR INACTIVATION OF POTENTIALLY INFECTIOUS SAMPLES WITH EBOLA VIRUS AND OTHER HIGHLY PATHOGENIC VIRAL AGENTS https://www.paho.org/hq/dmdocuments/2014/2014-cha-procedures-inactivation-ebola.pdf. Accessed 01 May 2020.

77. Centers for Disease C, Prevention, Gangadharan D, Smith J, Weyant R, Biosafety Recommendations for Work with Influenza Viruses Containing a Hemagglutinin from the A/goose/Guangdong/1/96 Lineage. MMWR Recomm Rep 2013;62: 1-7.

78. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P, European Network for Drug A, hypersensitivity Eigod, Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58: 854-63.

79. Romano A, Atanaskovic-Markovic M, Barbaud A, Bircher AJ, Brockow K, Caubet JC, Celik G, Cernadas J, Chiriac AM, Demoly P, Garvey LH, Mayorga C, Nakonechna A, Whitaker P, Torres MJ, Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy 2020;75: 1300-15.

80. Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, Bonini M, Heffler E, Klimek L, Laidlaw TM, Mulloli J, Nizankowska-Mogilnicka E, Park HS, Sanchez-Garcia S, Scadding G, Taniguchi M, Torres MJ, White AA, Wardynska A, Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy 2019;74: 28-39.

81. Muraro A, Lemanske RF, Jr., Castells M, Khan D, Simon HU, Bindslev-Jensen C, Burks W, Poulsen LK, Sampson HA, Worm M, Nadeau KC, Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 2017;72: 1006-21.

82. Eiwegger T, Huang L, San Diego KE, O’Mahony L, Upton J, Recent developments and highlights in food allergy. Allergy 2019;74: 2355-67.

83. Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, Yang Y, Liu B, Wang W, Wei C, Yang J, Ye G, Cheng Z, The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol 2020.

84. Pettersson ME, Koppelman GH, Flokstra-de Blok BM J, Kollen BJ, Dubois AEJ, Prediction of the severity of allergic reactions to foods. Allergy 2019;74: 1532-40.

85. Greuter T, Straumann A, Medical algorithm: Diagnosis and treatment of eosinophilic esophagitis in adults. Allergy 2020;75: 727-30.

86. Bonato G, Diascoridi L, Mutignani M, Faecal-oral transmission of SARS-COV-2: practical implications. Gastroenterology 2020.
87. Cianferoni A, Warren CM, Brown-Whitehorn T, Schultz-Matney F, Nowak-Wegrzyn A, Gupta RS. Eosinophilic esophagitis and allergic comorbidities in a US-population-based study. Allergy 2020;75: 1466-69.

88. Bousquet J, Akdis C, Stewart A, Khaled N, Anabwani G, Anderson R, Asher I, Beasley R, Bjorksten B, Burr M, Clayton T, Crane J, Ellwood P, Keil U, Lai C, Martinez F, Mitchell E, Montefort S, Pearce N, Shah J, Sibbalb B, Strachan D, von Mutius E, Weiland SK. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999;103: 125-38.

89. Gelincik A, Brockow K, Çelik G, et al. Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19. Allergy (submitted).

90. Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, Anderson R, Asher I, Beasley R, Bjorksten B, Burr M, Clayton T, Crane J, Ellwood P, Keil U, Lai C, Mallol J, Martinez F, Mitchell E, Montefort S, Pearce N, Shah J, Sibbalb B, Strachan D, von Mutius E, Weiland SK. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999;103: 125-38.

91. Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy 2015;70: 836-45.

92. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung D Y, Lipozencic J, Luenger TA, Muraro A, Novak N, Platts-Mills TA, Rosenbach L, Scheynius A, Simes F, Spiegel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006;61: 969-87.

93. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A, Czarnecka-Operacz M, Schafer T, Schmid-Grendelmeier P, Simon D, Szalai Z, Szepeitowski JC, Taieb A, Torrelo A, Werfel T, Ring J. European Dermatology Forum tEAoD, Venereology tEAoA, Clinical Immunology tETFoADEFoA, Airways Diseases Patients' Associations tESfDA, Psychiatry tESoPDGA, Asthma European N, the European Union of Medical S, Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018;32: 657-82.

94. Seegraber M, Worm M, Werfel T, Svensson A, Novak N, Simon D, Darsow U, Augustin M, Wollenberg A, Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. J Eur Acad Dermatol Venereol 2020;34: 1074-79.

95. Advice for Dermatology HCPs during Covid-19 Pandemic. 2020 20.04.2020]; Available from: https://www.bad.org.uk/. Accessed 22 Apr 2020.

96. Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S, Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol 2020.

97. Zuberbier T, Abbe R, Abdul Latiff AH, Baker D, Ballmer-Weber B, Bernstein JA, Bindslev-Jensen C, Brozzo Z, Buene Bedriok R, Canonica GW, Church MK, Craig T, Danilycheva IV, Dressler C, Ensina LF, Gimenez-Arnau A, Godse K, Gomiro M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Katelaris CH, Kocatürk E, Kulfthan K, Larenas-Linnemann D, Leslie TA, Maier M, Mathelthen-Fusade P, Meshkova RY, Metz M, Nast A, Nettis E, Oude-Elberink H, Raguenek S, Saini SS, Sanchez-Borges M, Schmid-Grendelmeier P, Staubach P, Sussman G, Toubi E, Vena GA, Vesterberg GA, Wedi B, Werner RN, Zhao Z, Maurer M, Endorsed by the following societies: Aaaai AADAAAABADBCDACCDD, Wao, The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73: 1393-414.

98. Imbalzano E, Casciaro M, Quartuccio S, Cincisio PL, Casco A, Calapai G, Gangemi S, Association between urticaria and virus infections: A systematic review. Allergy Asthma Proc 2016;37: 18-22.

99. Recalcati S, Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020;34: e212-e13.

100. Hedou M, Cazza F, Chary E, Hainaut E, Cazza C, Regnault M, Comment on "Cutaneous manifestations in COVID-19: a first perspective " by Recalcati S. J Eur Acad Dermatol Venereol 2020.

101. van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol 2020.
102. Venter C, Groetch M, Netting M, Meyer R, A patient-specific approach to develop an exclusion diet to manage food allergy in infants and children. Clin Exp Allergy 2018;48: 121-37.

103. Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M, Beyer K, Bounds-Lyensen C, Burks W, Ebisawa M, Eigenmann P, Knol E, Nadeau KC, Poulsen LK, van Ree R, Santos AF, du Toit G, Dhami S, Nurmatov U, Boloh Y, Makela M, O’Mahony L, Papadopoulos N, Sackesen C, Agache I, Angier E, Halken S, Jutel M, Lau S, Pfaar O, Ryan D, Sturm G, Varga EM, van Wijk RG, Sheikh A, Muraro A, Group EAIG, EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 2018;73: 799-815.

104. Sturm GJ, Varga EM, Roberts G, Mosbech H, Bilo MB, Akdis CA, Antolin-Amerigo D, Cichocka-Jarosz E, Gawlik R, Jakob T, Kosnik M, Lange J, Mingomataj E, Mitsias Dl, Ollert M, Oude Elberink JNG, Pfaar O, Pitsios C, Pravettoni V, Rueff F, Sm BA, Agache I, Angier E, Arasi S, Calderon MA, Fernandez-Rivas M, Halken S, Jutel M, Lau S, Pajno GB, van Ree R, Ryan D, Spranger O, van Wijk RG, Dhami S, Zaman H, Sheikh A, Muraro A, EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2018;73: 744-64.

105. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, Campi P, Sanz ML, Castells M, Demoly P, Pichler WJ, European Network of Drug A, the Eigodh, General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010;65: 1357-66.

106. Alvarez-Cuesta E, Madrigal-Burgaleta R, Angel-Pereira D, Urena-Tavera A, Zamora-Verduga M, Lopez-Gonzalez P, Berges-Gimeno MP, Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization. Allergy 2015;70: 784-94.

107. Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A, Schnyder B, Whitaker P, Cernadas JS, Bircher AJ, Enda ENEA, the EDAIG, Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013;68: 844-52.

108. Soyka MB, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, Kast JI, Akdis CA, Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-gamma and IL-4. J Allergy Clin Immunol 2012;130: 1087-96 e10.

109. Hirsch AG, Stewart WF, Sundaresan AS, Young AJ, Kennedy TL, Scott Greene J, Fung W, Tan BK, Schlueger RP, Kern RC, Linder A, Schwartz BS, Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy 2017;72: 274-81.

110. Gane SB, Kelly C, Hopkins C, Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology 2020;58: 299-301.

111. Vaira LA, Salzano G, Deiana G, De Riu G, Anosmia and Ageusia: Common Findings in COVID-19 Patients. Laryngoscope 2020.

112. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezhina Anselmo-Lima W, Bachert C, Barody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogiura J, Knill A, Kocks JH, Landis BN, Limpijung W, Lebeber S, Lorenou M, Meco C, Matricardi PM, O’Mahony L, Philipson CM, Ryan D, Schlosasser R, Sehnior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsahhale A, Jaugua M, Baudoin T, Balvers T, Battaglia P, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fischuk R, Grayson W, Goncalves PM, Grdinic B, Grigic V, Hamizan AW, Heinichen JV, Husain S, Ping TL, Ivaska J, Jakimovska F, Jovanovic L, Kakande E, Kamele R, Kaprischenko S, Kariyawasam HH, Kaufman H, Kjeldsen A, Klimmek L, Krzeczka A, Kopacheva Barsova G, Kim SW, Lal D, Letort JJ, Lopatin A, Mahdijouabi A, Mesbah A, Netkovski J, Nyenbe Tshipukane A, Obando-Valverde A, Okano M, Onnerci M, Ong YK, Orlandi R, Otori N, Ounnohugy K, Ozkan M, Peric A, Pizak J, Prokopakis E, Prepageran N, Psaltis A, Pugin B, Raftopoulos M, Rombaux P, Riechelmann H, Sahaout S, Sargsyan W, Searyoh K, Shkoukani M, Shkuryan AK, Sicak M, Smyth D, Snidvongs K, Sokic Kosak T, Stjarne P, Sutikno B, Steinsvag S, Tanttilipok P, Thanaviratananich S, Tran T, Urbaniec J, Valiuilas A, Vasquez de Aparicio C, Vieveva D, Virkkula PM, Vicente G, Voegels R, Wageman MM, Wardani RS, Welge-Lussen A, Witterick I, Wright E, Zabolotniy D, Zsolt B, Zwerdling P, European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020;58: 1-464.

113. Puhakka T, Makela MJ, Malstrom K, Uhari M, Savolainen J, Terho EO, Pulkininen M, Ruuskanen O, The common cold: effects of intranasal fluticasone propionate treatment. J Allergy Clin Immunol 1998;101: 726-31.
114. Hox V, Lourijsen E, Jordens A, Aasbjerg K, Agache I, Alobid I, Bachert C, Boussery K, Campo P, Fokkens W, Hellings P, Hopkins C, Klimek L, Makela M, Mosges R, Mullol J, Pujols L, Rondon C, Rudenko M, Toppila-Salmi S, Scadding G, Scheire S, Tomazic PV, Van Zele T, Wagemann M, van Boven JFM, Gevaert P, Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy 2020;10: 1.

115. Muraro A, Roberts G, Haikens S, Agache I, Angier E, Fernandez-Rivas M, Gerth van Wijk R, Jutel M, Lau S, Pajno G, Pfaar O, Ryan D, Sturm GJ, van Ree R, Varga EM, Bachert C, Calderon M, Canonica GW, Durham SR, Malling HJ, Wahn U, Sheikh A, EAACI guidelines on allergen immunotherapy: Executive statement. Allergy 2018;73: 739-43.

116. Pfaar O, Angier E, Muraro A, Haikens S, Roberts G, Algorithms in allergen immunotherapy in allergic rhinoconjunctivitis. Allergy 2020.

117. Pfaar O, Worm M. AIT und COVID-19. German Society of Allergy and Clinical Immunology (DGAKI). https://dgaki.de/gefaehrliche-defizite-in-der-allergologie-bleibt-der-patient-auf-der-strecke/ (Accessed April 21 2020).

118. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Har tog N, Hsieh EWY, Rider N, Dutmer CM, Vander Leek TK, Kim H, Chan ES, Mack D, Ellis AK, Lang D, Lieberman J, Fleischer D, Golden DBK, Wallace D, Portnoy J, Mosnaim G, Greenhawt M, COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic. The journal of allergy and clinical immunology In practice 2020.

119. Bourdin A, Bjermer L, Brightling C, Brusselle GG, Chanez P, Chung KF, Custovic A, Diamant Z, Diver S, Djukanovic R, Hamertlijnck D, Horvath I, Johnston SL, Kanniess F, Papadopoulos N, Papi A, Russell RJ, Ryan D, Samitas K, Tonia T, Zervas E, Goga M, ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. Eur Respir J 2019;54.

120. Darveau XJ, Lemanske RF, Jr., Infection-related asthma. The journal of allergy and clinical immunology In practice 2014;2: 658-63.

121. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A, Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? The Lancet Respiratory medicine 2020;8: 436-38.

122. Kaiser UB, Mirmira RG, Stewart PM, Our Response to COVID-19 as Endocrinologists and Diabetologists. J Clin Endocrinol Metab 2020;105.

123. American Academy of Allergy, Asthma, and Immunology. COVID-19 and asthma: What patients need to know. 2020. Available at https://www.aaaai.org/conditions-and-treatments/library/asthma-library/covid-asthma. Accessed April 17 2020.

124. Global Initiative for asthma. Recommendations for inhaled asthma controller medications. 2020. Available at https://ginasthma.org/recommendations-for-inhaled-asthma-controller-medications/. Accessed April 17 2020.

125. European Respiratory Society. COVID-19: Guidelines and recommendations directory. 2020. Available at https://www.ersnet.org/covid-19-guidelines-and-recommendations-directory. Accessed April 17 2020.

126. National Institute for Health and Care Excellence. Coronavirus (COVID-19). 2020. Available at https://www.nice.org.uk/covid-19. Accessed April 17 2020.

127. Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkoy YA, Gruchalla RS, Kattan M, Kercsmar CM, Khurana Hershey G, Kim H, Lebeau P, Liu AH, Szeffler SJ, Teach SJ, West JB, Wildfire J, Pongracic JA, Gern JE, Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am J Respir Crit Care Med 2017;196: 985-92.

128. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ, Jr., Calatroni A, Wildfire JJ, Gergen PJ, Cohen RT, Pongracic JA, Kercsmar CM, Khurana Hershey GK, Gruchalla RS, Liu AH, Zoratti EM, Kattan M, Grindle KA, Gern JE, Busse WW, Szeffler SJ, Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015;136: 1476-85.

129. Zhou F, Yu T, Bu R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395: 1054-62.

130. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory medicine 2020;8: 475-81.

131. Singhal T, A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020;87: 281-86.
132. Zheng YY, Ma YT, Zhang JY, Xie X, COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17: 259-60.

133. Pfaar O, Agache I, Bergmann KC, Bindslev-Jensen C, Bousquet J, Creticos PS, Devillier P, Durham SR, Hellings P, Kaul S, Kleine-Tebbe J, Klimek L, Jacobsen L, Jutel M, Muraro A, Papadopoulos NG, Rief W, Scadding GK, Schedlowski M, Shamji MH, Sturm G, van Ree R, Vidal C, Vieths S, Wedi B, Gerth van Wijk R, Frew AJ, Placebo effects in allergen immunotherapy - an EAACI Task Force Position Paper. Allergy 2020.

134. Kiecolt-Glaser JK, Heffner KL, Glaser R, Malarkey WB, Porter K, Atkinson C, Laskowski B, Lemeshow S, Marshall GD, How stress and anxiety can alter immediate and late phase skin test responses in allergic rhinitis. Psychoneuroendocrinology 2009;34: 670-80.

135. Vits S, Cesko E, Benson S, Rueckert A, Hillen U, Schadendorf D, Schedlowski M, Cognitive factors mediate placebo responses in patients with house dust mite allergy. PLoS One 2013;8: e79576.

136. Petrie KJ, Rief W, Psychobiological Mechanisms of Placebo and Nocebo Effects: Pathways to Improve Treatments and Reduce Side Effects. Annu Rev Psychol 2019;70: 599-625.

137. Schedlowski M, Enck P, Rief W, Bingel U, Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice. Pharmacol Rev 2015;67: 697-730.

138. Kemeny ME, Schedlowski M, Understanding the interaction between psychosocial stress and immune-related diseases: a stepwise progression. Brain Behav Immun 2007;21: 1009-18.

139. Dantzer R, Cohen S, Russo SJ, Dinan TG, Resilience and Immunity. Brain Behav Immun 2018;74: 28-42.

140. Food and Drug Administration. Clinical Trial Conduct During the COVID-19 Pandemic. Available at https://www.fda.gov/drugs/coronavirus-covid-19-drugs/clinical-trial-conduct-during-covid-19-pandemic. Accessed April 19 2020.

141. European Medicines Agency. Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic [https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclincialtrials_covid19_en.pdf]. Accessed April 19 2020.

142. Shrestha GS, Paneru HR, Vincent JL, Precision medicine for COVID-19: a call for better clinical trials. Crit Care 2020;24: 282.

143. Bonini S, Maltese G, COVID-19 clinical trials: quality matters more than quantity. Allergy 2020.
CONFLICT OF INTEREST:

Agache, Ioana
Dr. Agache reports an Associate Editor Allergy.

Akdis, Cezmi
Dr. Akdis reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kühne-Center for Allergy Research and Education, European Commission's Horison's 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, Scibase, advisory role in Sanofi/Regeneron, outside the submitted work.

Ansotegui, Ignacio
Dr. Ansotegui reports personal fees from Mundipharma, Roxall, Sanofi, MSD, Faes Farma, Hikma, UCB, Astra Zeneca, Stallergenes, Abbott, outside the submitted work.

Bachert, Claus
Dr. Bachert has nothing to disclose.

Bedbrook, Anna
Mrs Bedbrook has nothing to disclose.

Bonini, Matteo
Dr. Bonini has nothing to disclose.

Bosnic-Anticevich, Sinthia
Dr. Bosnic Anticevich reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan, outside the submitted work.
Bousquet, Jean
Pr Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed-Innov, outside the submitted work.

Brehler, Randolf
Dr. Brehler reports personal fees from ALK, Allergopharma, Astra Zeneca, Bancard, GSK, HAL, Leti, Merck, Novartis, Stallergenes, Takeda, Thermo fischer Novartis, other from ALK, Allergopharma, Novartis, Takeda, Bancard, Biotech Tools, Circassia, Genentech, Leti, outside the submitted work.

Breiteneder, Heimo
Dr. Breiteneder has nothing to disclose.

Brough, A Helen
Dr. Brough reports speaker fees from DBV Technologies and Sanofi and research support from ThermoFisher Scientific

Brussino, Luisa
Dr Brussino has nothing to disclose.

Canonica, G. Walter
Pr Canonica has nothing to disclose.

Cardona, Vicky
Dr Cardona reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermofisher, Stallergenes, outside the submitted work.
Carreiro-Martins, Pedro

Dr Carreiro-Martins has nothing to disclose.

Chinthrajah, Sharon

Dr. Chinthrajah reports grants from NIAID, CoFAR, Aimmune, DBV Technologies, Astellas, Regeneron, other from Alladapt, Genentech, Novartis, personal fees from Before Brands, outside the submitted work.

Chivato, Tomás

Dr. Chivato has nothing to disclose.

Cruz, Alvaro A

Dr Cruz reports grants and personal fees from GSK, AstraZeneca, grants from Sanofi, personal fees from Boehringer Ingelheim, Novartis, MYLAN, non-financial support from CHIESI, outside the submitted work.

Czarlewski, Wienczyslawa

Dr Czarlewski has nothing to disclose.

del Giacco, Stefano

Dr. del Giacco reports personal fees from AstraZeneca, Chiesi, Menarini; grants and personal fees from GSK, from Novartis, outside the submitted work.

Diamant, Zuzana

Apart from academic affiliations and assignments, ZD acts as Executive and Scientific Medical Director at a phase I/II pharmacological unit (QPS-NL), which performs clinical studies for...
pharmaceutical companies. In the past 3 years, ZD received honoraria, consultancy and speaker fees from Acucort, Astrazeneca, ALK, Aquilon, Boehringer Ingelheim, CSL, HAL Allergy, MSD, Sanofi-Genzyme.

**Dramburg, Stephanie**
Dr. Dramburg has nothing to disclose.

**Eiwegger, Thomas**
Dr. Eiwegger reports other from DBV, Regeneron; grants from Innovation fund Denmark, CIHR, He is the Co-I or scientific lead in three investigator initiated oral immunotherapy trials including the usage of biologicals supported by the Allergy and Anaphylaxis Program Sickkids and CIHR. He serves as associate editor for Allergy. He is on advisory boards for ALK.

**Fokkens, Wytske J**
Dr. Fokkens has nothing to disclose.

**Fonseca, Joao A**
Dr. Fonseca has nothing to disclose.

**Fritsch, Hans-Walter**
Mr. Fritsch has nothing to disclose.

**Gawlik, Radek**
Dr. Gawlik has nothing to disclose.

**Gelincik, Asli**
Dr. Gelincik has nothing to disclose.
Gotua, Maia:

Dr. Gotua has nothing to disclose.

Haatela, Tari

Pr Haahtela has nothing to disclose.

Hoffmann-Sommergruber, Karin

Dr. Hoffmann-Sommergruber has nothing to disclose.

Hox, Valeri

Dr. Hox reports personal fees from Consultant work for ALK, outside the submitted work.

Ivancevich, Juan Carlos

Dr. Ivancevich reports personal fees from Faes Farma, Abbott Colombia, Eurofarma Argentina, other from Lab. Casasco Argentina, outside the submitted work.

Jutel, Marek

Dr. Jutel reports personal fees from ALK-Abello, personal fees from Allergopharma, personal fees from Stallergenes, personal fees from Anergis, personal fees from Allergy Therapeutics, personal fees from Circassia, personal fees from Leti, personal fees from Biomay, personal fees from HAL, during the conduct of the study; personal fees from Astra-Zeneca, personal fees from GSK, personal fees from Novartis, personal fees from Teva, personal fees from Vectura, personal fees from UCB, personal fees from Takeda, personal fees from Roche, personal fees from Janssen, personal fees from Medimmune, personal fees from Chiesi, outside the submitted work.

Klimek, Ludger
Dr. Klimek reports grants and personal fees from Allergopharma, MEDA/Mylan, LETI Pharma, Sanofi; personal fees from HAL Allergie, Allergy Therapeut.;; grants from ALK Abelló, AstraZeneca, GSK, Inmunotk, Stallergenes, Quintiles, ASIT biotech, Lofarma, outside the submitted work; and Membership: ÚeDA ÝGHNOÝeutsche Akademie für Allergologie und klinische ImmunologieDNO-BV GPAÅAACI.

Knol, E. F.
Dr. Knol has nothing to disclose.

Kuna, Piotr
Pr Kuna has nothing to disclose.

Kvedariene, Violeta
Dr Kvedariene has nothing to disclose.

Larenas-Linnemann, Desiree
Dr Larenas-Linnemann reports personal fees from Allakos, Amstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Novartis, Sanofi, Siegfried, UCB, Alakos, Gossamer, grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Boehringer Ingelheim, Chiesi, Purina institute, outside the submitted work.

Latiff, Amir
Dr. Latiff has nothing to disclose.

Lauerma, Antti
Dr. Antti Lauerma has nothing to disclose.
Matricardi, Paolo

Dr. Matricardi has nothing to disclose.

Morais-Almeida, Mario

Dr. Morais-Almeida has nothing to disclose.

Mortz, Gotthard Charlotte

Dr. Mortz reports grants from Novartis, outside the submitted work.

Mullol, Joaquim

Pr Mullol has nothing to disclose.

Naclerio, Robert

Dr Naclerio reports personal fees from Sanofi, Regeneron, GSK, AstraZeneca, American Chemistry Council, Lyra, TASC, outside the submitted work.

Nadeau, Kari Christine

Dr. Nadeau reports grants and other from NIAID, FARE, Novartis, AnaptysBio, Adare Pharmaceuticals, Stallergenes-Greer, NHLBI, NIEHS, EPA, WAO Center of Excellence, Iggenix, Probio, Vedanta, Centecor, Seed, Immune Tolerance Network, NIH, Sanofi, Astellas, Nestle, BeforeBrands, Alladapt, ForTra, Genentech, Alimmune Therapeutics, DBV Technologies; personal fees and other from Regeneron; grants from EAT, Allergenis, Ukko Pharma; personal fees from AstraZeneca, ImmuneWorks, Cour Pharmaceuticals, outside the submitted work; In addition, Dr. Nadeau has a patent Inhibition of Allergic Reaction to Peanut Allergen using an IL-33 Inhibitor pending, a patent Special Oral Formula for Decreasing Food Allergy Risk and Treatment for Food Allergy pending, a patent Basophil Activation Based Diagnostic Allergy Test pending, a patent Granulocyte-based methods for detecting and monitoring immune system disorders pending, a
patent Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders pending, a patent Mixed Allergen Compositions and Methods for Using the Same pending, and a patent Microfluidic Device and Diagnostic Methods for Allergy Testing Based on Detection of Basophil Activation pending.

**O’Hehir, Robyn**
Prof O’Hehir has nothing to disclose.

**Ohta, Ken**
Pr Ohta has nothing to disclose.

**Okamoto, Yoshitaka,**
Dr. Okamoto has nothing to disclose.

**Ollert, Markus**
Dr. Ollert has nothing to disclose.

**O’Mahony, Liam**
Dr. O’Mahony reports personal fees from AHL, grants from GSK, outside the submitted work; .

**Onorato, Gabrielle L**
Dr. Onorato has nothing to disclose.

**Palomares, Oskar**
Dr. Palomares received research grants from Inmunotek S.L. and Novartis D’Oscar Palomares has received fees for giving scientific lectures from:Úllergy Therapeutics, Amgen, AstraZeneca, Diater,
GlaxoSmithKline, S.A, Inmunotek S.L, Novartis, Sanofi-Genzyme and Stallergenes and participated in advisory boards from Novartis and Sanofi-Genezyme.

Papadopoulos, Nikos G
Dr. Papadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare, outside the submitted work.

Patella, Vincenzo
Dr. Patella has nothing to disclose.

Pfaar, Oliver
Dr. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, MEDA Pharma/MYLAN, Anergis S.A., grants from Biomay, Circassia, Glaxo Smith Kline, personal fees from Mobile Chamber Experts (a GA\(^2\)LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL, NOVARTIS, SANOFI AVENTIS, Med Update Europe GmbH, streamedup! GmbH, outside the submitted work.

Regateiro, Frederico
Dr Regateiro reports personal fees from AstraZeneca, Novartis, Lusomedicamenta, Sanofi, GSK, outside the submitted work.

Rief, Winfried
Dr. Rief has nothing to disclose.

Riggioni, Carmen
Dr. Carmen Riggioni has nothing to disclose.

**Samolinski, Boleslaw**

Pr Samolinski has nothing to disclose.

**Sampath, Vanitha**

Dr. Sampath has nothing to disclose.

**Skypala, Isabel**

Dr. Skypala has nothing to disclose.

**Schedlowski, Manfred**

Dr. Schedlowski has nothing to disclose.

**Suppli Ulrik, Charlotte**

Dr. Charlotte Suppli Ulrik has nothing to disclose.

**Toppila-Salmi, Sanna**

Dr Toppila-Salmi reports grants from GSK, personal fees from ERT, Novartis, Sanofi Pharma, Roche, outside the submitted work.

**Torres, Maria Jose**

Dr. Torres has nothing to disclose.

**Traidl-Hoffmann, Claudia**
Dr. Traidl-Hoffmann reports grants and personal fees from Töpfer GmbH, Danone Nutricia, personal fees from Sanofi, La Roche Posay, Lilly Pharma, Novartis, grants from Sebapharma, Thermofischer, outside the submitted work.

Untersmayr-Elsenhuber, Eva
Dr. Untersmayr has nothing to disclose.

Valiulis, Arunas
Pr Valiulis has nothing to disclose.

Ventura, Maria Teresa
Dr. Ventura has nothing to disclose.

Walusia-Skorupa, Jolanta
Dr. Walusia-Skorupa has nothing to disclose.

Wang DY,
Dr. Wang has nothing to disclose.

Yorgancioglu, Arzu
Pr Yorgancioglu has nothing to disclose.

Zhang, Luo
Dr. Zhang has nothing to disclose.

Zuberbier, Torsten
Pr Zuberbier reports: Organizational affiliations: Committee member: WHO-Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA); Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI); Head: European Centre for Allergy Research Foundation (ECARF); President: Global Allergy and Asthma European Network (GA²LEN); Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO)
Suggested follow-up test (on indication)

**Mental health, CNS & psychosocial well being**

- Spirometry/Peak flow
- Lung volume testing
- Diffusion test
- (FeNO)
- Chest imaging
- 6-minute walk test with O2 saturation monitoring

**Lungs Respiratory system**

- Liver Liver system
  - Liver function test
  - Albumin
  - Coagulation (PT, PTT, INR, thrombocytes)

- Endocrinology system
  - Hormonal balance
  - Attend to weight and nutrition
  - Blood sugars and gastric protection if on oral corticosteroids

**Heart Cardiovascular system**

- Electrocardiogram
- Echocardiography
- Holter monitoring
- Exercise test

**Kidney Renal system**

- Kidney function
- Electrolytes
- Urinalysis

**Immune cells & inflammation Immune system**

- Lymphocytes, eosinophils
- Consider following inflammatory markers for trend to resolution: CRP, ESR, d-dimer, fibrinogen

**Skin Dermatology**

- Skin exams for resolution of rashes or thrombotic events
